This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-011325-r42hzazp | Do Vaccines Trigger Neurological Diseases? |
| cord-004078-d1pd09zj | Immunological specificity of synthetic sugarprotein antigens Polysaccharide- protein conjugates: a new generation of vaccines Meningococcal glycoconjugate vaccines efficacy, safety and effectiveness of pneumococcal conjugate vaccines Review on the immunogenicity and safety of PCV-13 in infants and toddlers Glycoconjugate vaccines: an update Carbohydrate vaccines: developing sweet solutions to sticky situations? |
| cord-017838-fbotc479 | The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? |
| cord-009381-q9s38fkh | Which BVD vaccine should I use? |
| cord-001260-6krujv2m | High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants Are there differences in immunogenicity and safety of vaccines according to the injection method? |
| cord-003656-7mzsaz7a | isolated from Struthio camelus Mycoplasmas and their host: emerging and re- emerging minimal pathogens Antibiotic residues in food: the African scenario DNA- antiviral vaccines: New developments and approaches- a review Immunization of animals: from DNA to the dinner plate DNA vaccines: an historical perspective and view to the future DNA vaccines: ready for prime time? |
| cord-017291-bhe34dky | results of the Flu Watch cohort study Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and metaanalysis Global role and burden of influenza in pediatric respiratory hospitalizations, 1982- 2012: a systematic analysis Estimating deaths due to influenza and respiratory syncytial virus Incidence of medically attended influenza during pandemic and post- pandemic seasons through the Influenza Incidence Surveillance Project Closure of schools during an influenza pandemic Prevention and control of seasonal influenza with vaccines recommendations of the Advisory Committee on Immunization Practices- United States, 2016- 17 influenza season Risk factors for influenza- associated severe acute respiratory illness hospitalization in a high HIV prevalence setting- South Africa Severe influenzaassociated respiratory infection in high HIV prevalence setting, South Africa Mortality amongst patients with influenza- associated severe acute respiratory illness, South Africa Maternal influenza and birth outcomes: systematic review of comparative studies Twenty- five years of outpatient influenza surveillance in South Africa Influenza seasonality in the tropics and subtropics- when to vaccinate? |
| cord-007733-zh8e76w7 | How much experience do we have with pandemic influenza virus vaccines? |
| cord-017841-57rm046y | Why are these numbers so high? |
| cord-257533-i85dyg8n | What are the Underlying Transmission Patterns of COVID-19 Outbreak? |
| cord-009947-0zz4x8li | If vaccination has been so successful, then why is it necessary to continually re- evaluate vaccination practice? |
| cord-003403-ypefqm71 | A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII Induction of potent Th1-type immune responses from a novel DNA vaccine for west nile virus New York isolate( WNV- NY1999) Development of vaccines against Zika virus Zika virus structural biology and progress in vaccine development Role of Zika Virus prM protein in viral pathogenicity and use in vaccine development Zika virus emergence in mosquitos in Southeastern Senegal Evolutionary enhancement of Zika virus infectivity in Aedes aegypti mosquitoes Assessing Seasonal risks for the introduction and mosquito- borne spread of Zika virus in Europe Zika virus vector competency of mosquitoes Aedes hensilli as a potential vector of Chikungunya and Zika viruses Outbreak of Zika virus infection, Chiapas State, Mexico, 2015, and first confirmed transmission by aedes aegypti mosquitoes in the Americas Autophagy and viral diseases transmitted by Aedes aegypti and Aedes albopictus Zika virus: Following the path of dengue and chikungunya? |
| cord-000050-tfcerilc | Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in chickens Are we ready for pandemic influenza? |
| cord-004518-jd1wxobz | Raška, Milan title: DNA vaccines: are they still just a powerful tool for the future? |
| cord-016371-zkawdcac | How) do aluminium adjuvants work? |
| cord-004181-exbs3tz7 | The Journal of Infectious Diseases Development of Streptococcus agalactiae vaccines for tilapia Streptococcal β protein has separate binding sites for human factor h and IgA- Fc Identification of group B streptococcal Sip protein, which elicits cross- protective immunity Immunotherapy of established( pre)malignant disease by synthetic long peptide vaccines A web resource for designing subunit vaccine against major pathogenic species of bacteria Prospects for control of emergimg infectious dyseases with plasmid DNA vaccines DNA vaccines: ready for prime time? |
| cord-021637-f5wwn45z | Company 2013 year- end earnings releases from Evaluate Pharma New scientific opportunities and old obstacles in vaccine development Immunizing children: can one shot do it all? |
| cord-021637-f5wwn45z | Improving vaccine supply and development: who needs what? |
| cord-027654-k0uby99n | SIVmacinduced immunodefi ciency AAV vectors: is clinical success on the horizon? |
| cord-002282-ldfa616a | Toward the global elimination of hepatitis B virus transmission Optimization of elastin- like polypeptide fusions for expression and purification of recombinant proteins in plants Plant- based edible vaccine against HBV Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen The twenty- year story of a plant- based vaccine against Hepatitis B: Stagnation or promising prospects? |
| cord-016222-dltsdqcm | World Health Organization Will Ebola change the game? |
| cord-005081-kxrzv16n | The natural question has been raised for years: Is it possible to develop some universal anti influenza A vaccine based on the agent's conservative proteins? |
| cord-005081-kxrzv16n | What are basic prospects opening before the vac cines constructed using state of the art genetic engi neering techniques? |
| cord-016508-39glgeft | The main question is: how to conceive a feasible long- term mechanism to minimize these risks faced by pharma companies? |
| cord-016508-39glgeft | Which global organizations should be responsible for this alternative model? |
| cord-005246-cskb0njm | conqueror, conquest? |
| cord-005246-cskb0njm | the requirements for high level expression of proteins, including glycoproteins Protection of mice against lethal Japanese encephalitis with a recombinant baculovirus vaccine Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein Carboxy- terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice Biological characterization of plaque- size variants of yellow fever virus in mosquitoes and mice Yellow fever: Victor, Victoria? |
| cord-016126-i7z0tdrk | v.2-a server for in silico prediction of allergens VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines High performance signal peptide prediction based on sequence alignment techniques Meningococcus B: control of two outbreaks by vaccination Protein identification and analysis tools on the ExPASy server Unipro UGENE NGS pipelines and components for variant calling, RNA- seq and ChIP- seq data analyses Discovering a vaccine against neosporosis using computers: is it feasible? |
| cord-258624-041cf99j | What is the predictive value of animal models for vaccine efficacy in humans? |
| cord-257027-q2y7fewk | Similarly, the possibility of a personalized vaccination strategy( appropriate dose, schedule and even molecular components of the vaccine?) has been suggested, which would be based on individual information, including genome- wide genetic information. |
| cord-002500-9p2n8tjx | : what can we learn from the race to develop novel vaccines? |
| cord-002500-9p2n8tjx | WHO collaborative study to assess the suitability of an interim standard for antibodies to Ebola virus Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation- assay- based diagnostic kit Which antibody functions are important for an HIV vaccine? |
| cord-163946-a4vtc7rp | If a coronavirus vaccine arrives, can the world make enough? |
| cord-018018-2yyv8vuy | In planta protein sialylation through overexpression of the respective mammalian pathway Transient Expression of Mammalian Genes in N. benthamiana to Modulate N- Glycosylation Immunogenicity of a subunit vaccine against Bacillus anthracis A plant- produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores How did international agencies perceive the avian influenza problem? |
| cord-259927-xh9cw9ao | Can a school- based hand hygiene program reduce asthma exacerbations among elementary school children? |
| cord-006890-81wv1s33 | Thus, the main issues to be critically addressed are dealing with vaccine safety and may be summarized in two questions: how to achieve an acceptable balance between requested speed and safety aspects? |
| cord-006890-81wv1s33 | how to assess quickly but reliably immunogenicity and efficacy of candidate vaccines or more specifically, in the absence of a relevant animal model, what is the minimal acceptable fast- track toxicity program ethically acceptable before going to Phase I trial? |
| cord-016178-2ix6c0he | A model system for edible vaccination using recombinant avidin produced in corn seed Mechanisms of coronavirus cell entry mediated by the viral spike protein Plant glycans: friend or foe in vaccine development? |
| cord-016178-2ix6c0he | Is the bronchus- associated lymphoid tissue( BALT) an integral structure of the lung in normal mammals, including humans? |
| cord-016178-2ix6c0he | The SARS wake- up call Is BALT a major component of the human lung immune system? |
| cord-004348-4jdn4kw6 | Would you volunteer to be quarantined and infected with influenza virus? |
| cord-004348-4jdn4kw6 | vaccines induce diverse T- cell responses in young children Live attenuated influenza vaccine in children induces B- cell responses in tonsils Influenza vaccine effectiveness against 2009 pandemic influenza a(H1N1) virus differed by vaccine type during 2013- 2014 in the United States Intranasal influenza vaccine: why does Canada have different recommendations from the USA on its use? |
| cord-261301-8mw2kpmr | where does antibody stand? |
| cord-266202-3qku90ml | syndrome Zika vaccine development- current progress and challenges for the future Risk in vaccine research and development quantified Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study Who will answer the call in the next outbreak? |
| cord-003567-h8uq5z8b | : how large are the expected losses? |
| cord-003567-h8uq5z8b | Can we predict the next influenza pandemics? |
| cord-003567-h8uq5z8b | If a pandemic similar to that of 1918 occurred today, how would the devastation compare? |
| cord-271153-c0aw6jkz | The public health emergency management system in China: trends from Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore Coronavirus Resource Center Early response to the emergence of influenza A( H7N9) virus in humans in China: the central role of prompt information sharing and public communication COVID-19: too little, too late? |
| cord-006892-n2ncamqh | Better influenza vaccines for older people: what will it take? |
| cord-006892-n2ncamqh | different virus- like particles be used for primeboost vaccination? |
| cord-264356-3zu4w0a9 | Can an effective SARS- CoV-2 vaccine be developed for the older population? |
| cord-266199-smlq11y9 | state- of- the- art Ten years of PCV2 vaccines and vaccination: is eradication a possibility? |
| cord-011486-5osu6hdu | : is their surveillance needed? |
| cord-011486-5osu6hdu | An update of paediatric intussusception incidence in Singapore: 1997- 2007, 11 years of intussusception surveillance Safety and efficacy of a pentavalent human- bovine( WC3) reassortant rotavirus vaccine Update on intussusception following rotavirus vaccine administration: World Health Organization Reevaluating the potential impact and cost- effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study Improving rotavirus vaccine coverage: can newer- generation and locally produced vaccines help? |
| cord-011486-5osu6hdu | During 2015- 2018: Dynamic Changes in Rotavirus Genotypes From Equine- Like G3 to Typical Human G1/ G3 Rotavirus diarrhea in hospitalized children under 5 years of age in Vientiane Rotavirus genotypes in Malaysia and universal rotavirus vaccination Sentinel surveillance for rotavirus in children< 5 years of age admitted for diarrheal illness to Yangon Children's hospital First detection of DS-1-like G1P[8] human rotavirus strains from children with diarrhoea in the Philippines Molecular characterization of rotavirus diarrhea among children aged under five years in the Philippines Is your drinkingwater safe? |
| cord-003926-ycdaw2vh | Isolations and serological specificity Zika virus: Following the path of dengue and chikungunya? |
| cord-003926-ycdaw2vh | Tip of the iceberg? |
| cord-021937-p9vqpazu | Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to Seroprevalence of hepatitis A and associated socioeconomic factors in young healthy Korean adults Urbanization and geographic expansion of zoonotic arboviral diseases: mechanisms and potential strategies for prevention Development of health biotechnology in developing countries: can private- sector players be the prime movers? |
| cord-021937-p9vqpazu | The Indian and Chinese health biotechnology industries: potential champions of global health? |
| cord-267897-w4pbq2lb | toxoid Induction of resistance to Schistosoma mansoni by immunization with subfractions of worms Protection against Schistosoma mansoni achieved by immunization with sonicated parasite Updated aluminum pharmacokinetics following infant exposures through diet and vaccination Aluminum and Alzheimer's disease: after a century of controversy, is there a plausible link? |
| cord-003806-ctass7hz | A question motivating this analysis was one step deeper in the complexity of these effects: does the self- limiting effect of adaptive immunity worsen when revertant is present? |
| cord-003806-ctass7hz | Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it? |
| cord-003806-ctass7hz | Following Yellow Fever Vaccination? |
| cord-003764-141u6ax7 | How Far From Clinical Use? |
| cord-003764-141u6ax7 | The structural basis for membrane binding and pore formation by lymphocyte perforin DNA vaccines and apoptosis: to kill or not to kill? |
| cord-003764-141u6ax7 | What if? |
| cord-268501-z4oztgi0 | , Clarisa B. title: What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? |
| cord-272241-2fwz8z8n | the beginning of another SARS- like pandemic? |
| cord-025366-haf542y0 | Addressing parents'concerns: do vaccines cause allergic or autoimmune diseases? |
| cord-025366-haf542y0 | How the Anti- Vaccine Movement Threatens Us All Ensuring the optimal safety of licensed vaccines: a prospective of the vaccine research, development, and manufacturing companies Active surveillance for adverse events: the experience of the Vaccine Safety Datalink Project Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment network Addressing parents'concerns: do multiple vaccines overwhelm or weaken the infant's immune system? |
| cord-025366-haf542y0 | When a child experiences an adverse event following receipt of a vaccine, it often raises the question"Was this vaccine necessary"? |
| cord-025366-haf542y0 | Why should we care about a small number of parents who are worried about vaccines for their children? |
| cord-032600-lldbjm77 | Is there an optimal formulation and delivery strategy for subunit vaccines? |
| cord-032600-lldbjm77 | So what is my choice for the sixth revolution? |
| cord-280172-6o1gqe8v | How good is automated protein docking? |
| cord-273526-ah0dvnxv | Two years after pandemic influenza A/2009/ H1N1: what have we learned? |
| cord-005400-50lmj4op | But why was the mortality rate so high? |
| cord-005400-50lmj4op | Would it be possible to repeat this outstanding success with another infectious disease? |
| cord-005400-50lmj4op | immunizations Is global measles eradication feasible? |
| cord-267666-i7uuf3ck | Asian 1396 Pacific journal of tropical medicine Coronaviruses: Candidate Drugs for SARS- CoV-2 Treatment? |
| cord-267666-i7uuf3ck | CD4+ regulatory T cells: mechanisms of 1036 induction and effector function Atypical MHC class II- expressing antigen- presenting 1224 cells: can anything replace a dendritic cell? |
| cord-000452-1gd006zy | Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus Intradermal vaccine delivery: will new delivery systems transform vaccine administration? |
| cord-000452-1gd006zy | What happens if intradermal injections of rabies vaccine are partially or entirely injected subcutaneously? |
| cord-000452-1gd006zy | fabrication, mechanics and transdermal drug delivery Polymer microneedles for controlled- release drug delivery Jet gun or syringe? |
| cord-000452-1gd006zy | using microneedles induces superior protection to intramuscular immunization Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle- free device in Cuba Clinical safety and efficacy of a powdered hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non- inferiority trial Intradermal vaccination to protect against yellow fever and influenza Penetration- enhanced ultrasharp microneedles and prediction on skin interaction for efficient transdermal drug delivery Induction of antigen- specific CD8? |
| cord-000262-4owsb0bg | -would there be sufficient production capacity to meet needs[ 38]? |
| cord-000262-4owsb0bg | Had there been''overpreparation''? |
| cord-000262-4owsb0bg | How well are we managing the influenza A/ H1N1 pandemic in the UK? |
| cord-000262-4owsb0bg | The truth about Tamiflu? |
| cord-018040-k0h5ejjt | Statements like"What message are we sending to our elementary students when we inoculate them for a sexually transmitted disease in the third grade?" |
| cord-018040-k0h5ejjt | What may be the mechanism of higher immunogenicity exhibited by particulate antigens compared to soluble ones and does the size of these particles matter? |
| cord-018040-k0h5ejjt | Who's afraid of Gardasil? |
| cord-279260-tdvb0fhv | The pathogenicity of SARS- CoV-2 in hACE2 transgenic mice Rapid generation of a mouse model for Middle East respiratory syndrome Correlates of protection induced by vaccination Correlates of protection to influenza virus, where do we go from here? |
| cord-278417-ty4wbtkv | The author has nothing to disclose Covid-19: A comprehensive review of a formidable foe and the road ahead Pandemic preparedness: Developing vaccines and therapeutic antibodies for COVID-19 The early landscape of COVID-19 vaccine development in the UK and rest of the world BCG- induced trained immunity: can it offer protection against COVID-19? |
| cord-257722-7rmzaau4 | HP55/ PLGA nanoparticles promote immune protection Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B Targeted delivery of GP5 antigen of PRRSV to M cells enhances the antigen- specific systemic and mucosal immune responses Targeting nanoparticles to M cells with non- peptidic ligands for oral vaccination Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide- coupled chitosan Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell- homing peptide selected by phage display technique Attuning hydroxypropyl methylcellulose phthalate to oral delivery vehicle for effective and selective delivery of protein vaccine in ileum Combinatorial approach of antigen delivery using M cell- homing peptide and mucoadhesive vehicle to enhance the efficacy of oral vaccine Can bioadhesive nanoparticles allow for more effective particle uptake from the small intestine? |
| cord-257722-7rmzaau4 | Nanogel- based nasal ghrelin vaccine prevents obesity Intranasal drug delivery: how, why and what for? |
| cord-257722-7rmzaau4 | Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? |
| cord-269448-1jikrn37 | Is it time to change strategies? |
| cord-016903-z2vqfq98 | A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Long- term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T- cell repertoire, which may be the basis for an imbalance in the cyrokine production profile in elderly persons Human immunosenescence: is it infectious? |
| cord-016903-z2vqfq98 | District guidelines for yellow fever surveillance Persistence of neutralizing antibody 30- 35 years after immunization with 17D yellow fever vaccine Advanced age a risk factor for illness temporally associated with yellow fever vaccination Thymic involution in aging Thymic involution with ageing: obsolescence or good housekeeping? |
| cord-016903-z2vqfq98 | For example, during influenza epidemics, Barker and Mullooly reported two deaths per 100,000 healthy people below 65 years ofage compared with 797 per 100,000 in those over 65 with two or more high- risk conditions? |
| cord-016903-z2vqfq98 | Hence, the accumulation of CMV- specific T- cells substantially constricts the diversity of the T- cell repertoire"and leads to the production ofproinflammatory cytokines, such as gamma interferon and tumor necrosis factor alpha.'? |
| cord-016903-z2vqfq98 | Vaccines supplemented with the DNA of cytokines( e.g., IL-2, IL-? IL- I2, IL- IS or IL-21), chemokines or costirnulatory molecules may magnify immune responses by generating more and long- lived memory T_ceIIs83- 85and may overcome immunodominance.' |
| cord-282360-byqhzyzi | as carriers of foreign antigens Oral vaccine delivery: can it protect against non- mucosal pathogens? |
| cord-263619-p17oomzn | IL-10 during measles in Zambian children Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine Communicating science to the public: MMR vaccine and autism Measles eradication: is it in our future? |
| cord-263619-p17oomzn | The development of a plant- based vaccine for measles Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa Has the 2005 measles mortality reduction goal been achieved? |
| cord-263619-p17oomzn | The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants Can measles be eradicated globally? |
| cord-276907-b855tj7x | Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies Tackling drug resistant infections globally: Final report and recommendation How can vaccines contribute to solving the antimicrobial resistance problem? |
| cord-016713-pw4f8asc | ( review) Pathogen recognition and development of particulate vaccines: does size matter? |
| cord-016713-pw4f8asc | : what are the benefits for the elderly? |
| cord-016713-pw4f8asc | I( IGF- I) Immunogenicity in mice of a cationic microparticle- adsorbed plasmid DNA encoding Japanese encephalitis virus envelope protein Vaccine potential of cytosolic proteins loaded fibrin microspheres of Cryptococcus neoformans in BALB/ c mice Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B Comparing the effect of IL-12 genetic adjuvant and alum non- genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzaespecific long- term mucosal immune responses in the nasopharynx Nanoparticles as carriers for nasal vaccine delivery DNA vaccines: ready for prime time? |
| cord-016713-pw4f8asc | basic studies and applications Immune responses against a new HIV-1 p24-gp41/ pCAGGS- IL-12 DNA vaccine in Balb/ c mice Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation Live attenuated AIDS viruses as vaccines: promise or peril? |
| cord-016713-pw4f8asc | human immunodeficiency virus type 1 Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? |
| cord-263277-m4too6ob | : Is there significant news? |
| cord-263277-m4too6ob | How can knowledge and technologies contribute towards removing current roadblocks? |
| cord-263277-m4too6ob | What does the future offer in terms of next generation vaccines? |
| cord-263277-m4too6ob | Where are we? |
| cord-265757-8ces57rn | : leucocytosis explained? |
| cord-265757-8ces57rn | How best to estimate the global burden of pertussis? |
| cord-265757-8ces57rn | The lymphocytosis explained? |
| cord-011370-as2v2c2h | /TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi- Pasteur CYD vaccine? |
| cord-011370-as2v2c2h | A prospective study on the impact and out- of- pocket costs of dengue illness in international travelers Travel vaccine preventable diseases- updated logarithmic scale with monthly incidence rates What proportion of international travellers acquire a travel- related illness? |
| cord-011370-as2v2c2h | The first licensed dengue vaccine: can it be used in travelers? |
| cord-011370-as2v2c2h | What is the prospect of a safe and effective dengue vaccine for travelers Mosquito repellents for the traveller: does picaridin provide longer protection than DEET? |
| cord-287824-zg5akivn | Influenza antivirals and resistance: The next 10 384 years? |
| cord-000194-cwzpb8fu | A virus with defective M2 ion channel activity as a live vaccine Immunogenicity and effi cacy of Russian live attenuated and US inactivated infl uenza vaccines used alone and in combination in nursing home residents Does infl uenza vaccination exacerbate asthma in children? |
| cord-000194-cwzpb8fu | Amid mayhem in Turkey, experts see new chances for research Safety and immunogenicity of an inactivated adjuvanted whole- virion infl uenza A( H5N1) vaccine: a phase I randomised controlled trial Human transmission but no pandemic in Indonesia Silent spread of H5N1 in vaccinated poultry Emergence and predominance of an H5N1 infl uenza variant in China Avian fl u to human infl uenza Making better infl uenza virus vaccines? |
| cord-000194-cwzpb8fu | Are these signs of development of some degree of immunity to virus, containing its replication and thus causing milder infection in naturally infected mammals? |
| cord-000194-cwzpb8fu | What are the consequences of vaccination for existing infl uenza( H5N1) infection, the extent of serologic cross- reactivity between the most closely related types of the virus, and the role in clinical protection? |
| cord-000194-cwzpb8fu | vaccines against infection with A/ Vietnam/1203/04(H5N1) virus in ferrets Detection of anti- H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted infl uenza A/ Duck/ Singapore/97 vaccine Characterization of the reconstructed 1918 Spanish infl uenza pandemic virus Preparing for the next pandemic Induction of proinfl ammatory cytokines in human macrophages by infl uenza A( H5N1) viruses: a mechanism for the unusual severity of human disease? |
| cord-289961-7q2wkwrf | What controls the melting properties of DNA- linked gold nanoparticle assemblies? |
| cord-035016-ipv8npdy | May Who should get the Covid-19 vaccine first? |
| cord-035016-ipv8npdy | Pooling Knowledge: Private Medicine vs. Public Health? |
| cord-035016-ipv8npdy | The rush to create a Covid-19 vaccine may do more harm than good Collective intelligence, not market competition, will deliver the best Covid-19 Vaccines As politics trumps science in the race for a vaccine, who will protect public health? |
| cord-035016-ipv8npdy | Yet the criteria used by regulators to allow a vaccine on the market are not necessarily responding to the critical question at hand: which vaccine has the potential to significantly impact global public health outcomes for COVID-19? |
| cord-018497-oy7hsrpt | By using economic evaluation we are essentially trying to answer the following questions[ 5]: 1) Is the vaccination program under study worth doing compared to alternative ways of using the same resources? |
| cord-018497-oy7hsrpt | Discounting costs and effects: a reconsideration Discounting for health effects in cost- benefit and cost- effectiveness analysis Does NICE have a cost- effectiveness threshold and what other factors influence its decisions? |
| cord-018497-oy7hsrpt | In other words: should the( health care) resources be spent on such a vaccination program, and not on something else? |
| cord-018497-oy7hsrpt | More specifically, if we are deciding to vaccinate against a particular disease, whom should we vaccinate, at which age, with which vaccine and how should the vaccine be delivered and administered in order to deploy our scarce resources in the most efficient way? |
| cord-018497-oy7hsrpt | The question then is, how to determine K? |
| cord-280459-y0tbvs3t | how, why and what for? |
| cord-289360-h6wvx7gw | A strategy to estimate unknown viral diversity in mammals Is the debate and"pause"on experiments that alter pathogens with pandemic potential influencing future plans of graduate students and postdoctoral fellows? |
| cord-289360-h6wvx7gw | mBio Is virology dead? |
| cord-274112-6t0wpiqy | A pandemic warning? |
| cord-261876-7rsc803x | Does SARS- CoV-2 has a longer incubation period than SARS and MERS? |
| cord-261876-7rsc803x | NL63: a clinically important virus? |
| cord-261876-7rsc803x | when is an exposed individual known to be disease free? |
| cord-279629-t1xjy12y | An evolutionary RGD motif in the spike protein of SARS- CoV-2 may serve as a potential high risk factor for virus infection? |
| cord-279629-t1xjy12y | When will a coronavirus vaccine be ready?". |
| cord-290031-vffa1bu0 | If Flu and COVID-19 Overlap? |
| cord-018677-gmitz3gg | And for how long are these beneficiaries entitled to receive the vaccine? |
| cord-018677-gmitz3gg | However, controversy surrounds the boundaries for the group of persons entitled to receive the investigational vaccine at the conclusion of the study-only participants in the trial, all persons living in the same region, or all persons living in the same country? |
| cord-018677-gmitz3gg | The Alaska H. influenzae Vaccine Study Group Efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera- endemicarea Global reduction of Hib disease: what are the next steps? |
| cord-018677-gmitz3gg | The safety, immunogenicity, and transmissibility of single- dose live oral cholera vaccine CVD 103-HgR in 25- 59 month old Indonesian children The ethical challenge of infection- inducing challenge experiments Infectious disease experimentation involving human volunteers Initial clinical evaluation of new vaccine candidates: investigators'perspective of phase I and phase II clinical trials of safety, immunogenicity, and preliminary efficacy Evaluating new vaccines for developing countries: efficacy or effectiveness? |
| cord-018677-gmitz3gg | When are placebo- controlled trials ethically acceptable? |
| cord-285982-1a5u7uux | recent advances in the cytotoxic T- Iymphocyte platform"spotty business DNA vaccines: ready for prime time? |
| cord-254513-7d10vd86 | An Introduction What is twitter Interest communities and flow roles in directed networks: the twitter network of the uk riots Information network or social network? |
| cord-254513-7d10vd86 | The structure of adolescent romantic and sexual networks Galaxyscope: Finding the"truth of tribes"590 on social media Tweeting from left to right: Is online political communication more than an echo chamber? |
| cord-254513-7d10vd86 | Users Enjoy the Opportunities for Political Debate and Engagement that Social Media Facilitates, But Many More Express Resignation, Frustration Over the Tone and Content of Social Platforms Echo chamber? |
| cord-254513-7d10vd86 | what echo chamber? |
| cord-258626-p469ysi8 | ( although a specific disease may not commonly be seen, the organism is ubiquitous in the environment and therefore poses risk to the individual or population);( 3) the risk of the individual for exposure to the disease( indoor- only animal vs free- roaming individual, regional variations of occurrence);( 4) the efficacy of the vaccine( does the vaccine prevent infection or simply ameliorate some signs or length of disease?);( 5) the risks associated with administering the vaccine( are the risks associated with that vaccine greater than the risk of the disease?);( 6) the potential for zoonotic disease;( 7) the route of infection or transmissibility. |
| cord-258626-p469ysi8 | ( although a specific disease may not commonly be seen, the organism is ubiquitous in the environment and therefore poses risk to the individual or population);( 3) the risk of the individual for exposure to the disease( indoor- only animal vs free- roaming individual, regional variations of occurrence);( 4) the efficacy of the vaccine( does the vaccine prevent infection or simply ameliorate some signs or length of disease?);( 5) the risks associated with administering the vaccine( are the risks associated with that vaccine greater than the risk of the disease?);( 6) the potential for zoonotic disease;( 7) the route of infection or transmissibility. |
| cord-258626-p469ysi8 | Criteria for assigning vaccines into these categories, and a third category,"generally not recommended,"are based on:( 1) morbidity and mortality associated with the specific disease( does the organism cause serious illness or does it cause a mild, transient disease that may pose only minimal risk to the individual or population?); |
| cord-258626-p469ysi8 | If an owner brings a Labrador retriever puppy to the veterinarian for"whatever vaccines he needs,"it is up to the practitioner to ask"will he be a hunting dog, will he be used in field trials, will he be exposed to wildlife and waterways?" |
| cord-258626-p469ysi8 | Who better to disseminate knowledge about veterinary medicine to the general public than veterinarians? |
| cord-283475-28900qlr | The cost structure of routine infant immunization services: a systematic analysis of six countries Can thermostable vaccines help address cold- chain challenges? |
| cord-271250-ywb26cq6 | The adjuvant LT- K63 can restore delayed maturation of follicular dendritic cells and poor persistence of both protein- and polysaccharide- specific antibody- secreting cells in neonatal mice Adjuvants enhancing cross- presentation by dendritic cells: the key to more effective vaccines? |
| cord-271250-ywb26cq6 | a meta- analysis Immunobiology of HPV and HPV vaccines Comparative immunogenicity and safety of human papillomavirus( HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9- 14 years: results to month 12 from a randomized trial Adjuvants in tuberculosis vaccine development TB vaccine development and the end tb strategy: importance and current status NOD2 and toll- like receptors are nonredundant recognition systems of mycobacterium tuberculosis Multi- stage subunit vaccines against mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG- prime boost? |
| cord-271250-ywb26cq6 | opportunities and challenges What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? |
| cord-260956-w6wxsg4p | Newcastle disease vaccines — A solved problem or a continuous challenge? |
| cord-260956-w6wxsg4p | Newcastle disease virus outbreaks: vaccine mismatch or inadequate application? |
| cord-260956-w6wxsg4p | vaccines represent the future? |
| cord-303447-3a7jxl34 | who was the source? |
| cord-305488-vk59ghjm | Avian paramyxovirus serotype-1: a review of disease distribution, clinical symptoms, and laboratory diagnostics Newcastle disease virus outbreaks: vaccine mismatch or inadequate application? |
| cord-003828-bhfghcby | A streptococcus and mammalian muscle Spreading of T- cell autoimmunity to cryptic determinants of an autoantigen Antiviral immune responses: triggers of or triggered by autoimmunity? |
| cord-003828-bhfghcby | Can vaccines cause MS and( ii) can vaccines provoke or trigger relapses in patients with MS? |
| cord-003828-bhfghcby | Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity Immunization in patients with multiple sclerosis Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis Epstein- Barr virus and multiple sclerosis Coronaviruses in brain tissue from patients with multiple sclerosis Active human herpesvirus 6 infection in patients with multiple sclerosis Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing- remitting multiple sclerosis Multiple sclerosis, sporadic creutzfeldt- jakob disease and bovine spongiform encephalopathy: are they autoimmune diseases evoked by acinetobacter microbes showing molecular mimicry to brain antigens? |
| cord-003828-bhfghcby | The neuro- paralytic accidents of antirabies treatment Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis? |
| cord-003828-bhfghcby | The risk of relapses in multiple sclerosis during systemic infections Relapsing encephalomyelitis following the use of influenza vaccine Ocular abnormalities after influenza immunization Acute transverse myelitis after influenza vaccination: magnetic resonance imaging findings Optic neuritis after influenza vaccination Diffuse myelitis associated with rubella vaccination Diffuse myelitis associated with rubella vaccination Transverse myelitis after measles, mumps, and rubella vaccine Optic neuritis complicating measles, mumps, and rubella vaccination Optic neuritis following measles/ rubella vaccination in two 13-year- old children Relapsing acute encephalopathy: a complication of diphtheria- tetanus- poliomyelitis immunization in a young boy Multiple sclerosis and vaccination Central- nervous- system demyelination after immunisation with recombinant hepatitis B vaccine Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? |
| cord-003828-bhfghcby | authors: Zrzavy, Tobias; Kollaritsch, Herwig; Rommer, Paulus S.; Boxberger, Nina; Loebermann, Micha; Wimmer, Isabella; Winkelmann, Alexander; Zettl, Uwe K. title: Vaccination in Multiple Sclerosis: Friend or Foe? |
| cord-255734-038xu4hq | Can the virus establish persistent infection and can humans be repeatedly infected? |
| cord-255734-038xu4hq | Finally, if SARS fails to return, how will vaccine manufacturers test candidate vaccines for efficacy? |
| cord-255734-038xu4hq | If we define the ability of the virus to replicate in monocytes/ macrophages can we be assured that antibody- dependent enhancement will not be a problem for a SARS vaccine? |
| cord-255734-038xu4hq | What are the viral virulence factors and can we use this information to develop an attenuated strain? |
| cord-255734-038xu4hq | What is the role of lymphocytic infiltrates and do alveolar macrophages enhance disease or control infection? |
| cord-296886-0bma2749 | ( IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon DNA and RNA- based vaccines: Principles, progress and prospects DNA vaccines- A modern gimmick or a boon to vaccinology? |
| cord-296886-0bma2749 | Progress and challenges Synthetic DNA vaccine strategies against persistent viral infections DNA vaccines: Ready for prime time? |
| cord-302155-hksmt48i | Can Ebola virus vaccines have universal immune correlates of protection? |
| cord-293234-ouykx6g5 | What does the odds ratio estimate in a case- control study? |
| cord-293234-ouykx6g5 | preliminary mid- season effectiveness estimates: reason for concern, confounding or are we following the right track? |
| cord-288868-qfdxri93 | In addition, the isolated case in December 2003 was caused by a virus with highest sequence homology to palm civets West Nile virus: where are we now? |
| cord-288868-qfdxri93 | Pandemic influenza: a zoonosis? |
| cord-275538-c44gmu22 | Efficacy of the vaccine( does the vaccine prevent infection or simply ameliorate some signs or length of the disease?) |
| cord-275538-c44gmu22 | If an owner brings a Labrador Retriever puppy to the veterinarian for''whatever vaccines it needs,''it is up to the practitioner to ask:''Will it be a hunting dog, will it be used in field trials, or will it be exposed to wildlife and waterways?'' |
| cord-275538-c44gmu22 | Morbidity and mortality associated with the specific disease( does the organism cause serious illness, or does it cause a mild transient disease that may pose only minimal risk to the individual or population?) |
| cord-275538-c44gmu22 | Risks associated with administering the vaccine( are the risks associated with that vaccine greater than the risk of the disease?) |
| cord-273099-zkk5d6gd | Immunizations in the United States: success, structure, and stress The vaccine industry: does it need a shot in the arm? |
| cord-273099-zkk5d6gd | Which of the following is the process by which vaccines protect not only those who receive them but also those who can not or do not receive the vaccine? |
| cord-273099-zkk5d6gd | Why are pharmaceutical companies gradually abandoning vaccines? |
| cord-289599-7vsynfgn | Are we rushing too much? |
| cord-289599-7vsynfgn | How much time is required? |
| cord-289599-7vsynfgn | Why are some animal experiments poor predictors of human outcomes and responses? |
| cord-296469-h0ma163u | Given the health, social and economic impact of infectious diseases with pandemic potential, there has been much attention to these microbial threats and, not surprisingly, the first question is always,''Is there a vaccine? |
| cord-296469-h0ma163u | How to deal with vaccine hesitancy? |
| cord-009383-ozx5u0t3 | ( 1996 Roy( what's already available? |
| cord-009383-ozx5u0t3 | ( 2) Will the vectored vaccine give a manufacturing advantage compared to what's already available? |
| cord-009383-ozx5u0t3 | ( 3) Will the vectored vaccine provide improved safety compared to what's already available? |
| cord-009383-ozx5u0t3 | ( 5) Will the vectored vaccine increase the duration of immunity compared to what's already available? |
| cord-009383-ozx5u0t3 | ( 6) Will the vectored vaccine be more convenient to store compared to what's already available? |
| cord-009383-ozx5u0t3 | ( 7) Is the vectored vaccine compatible with other vaccines? |
| cord-018969-0zrnfaad | Where have all the bees gone? cord-018969-0zrnfaad What Is Causing CCD? cord-311331-l7dehit8 Can controversial nanotechnology promise drug delivery? cord-301876-d2j9wpqk The SARS- CoV-2 vaccine pipeline: an overview SARS vaccines: where are we? cord-262282-9xh51cd1 : What have we learned? cord-262282-9xh51cd1 A review of Dengvaxia ®: Development to deployment DNA vaccines: Technology and application as anti- parasite and anti- microbial agents DNA vaccines- How far from clinical use? cord-262282-9xh51cd1 Can a virus transmit even more actively than SARS- CoV-2? cord-262282-9xh51cd1 Can more active transmission be accompanied by higher virulence? cord-262282-9xh51cd1 What factors shape phage pharmacokinetics and bioavailability? cord-283405-aozxvxxs Do the placental barrier, parasite genotype and Toll- like receptor polymorphisms contribute to the course of primary infection with various Toxoplasma gondii genotypes in pregnant women? cord-283405-aozxvxxs The effects of yellow fever immunization( 17DD) inadvertently used in early pregnancy during a mass campaign in Brazil Should expectant mothers be vaccinated against flu? cord-283405-aozxvxxs What does epidemiology tell us about risk factors for herpes zoster? cord-302268-dmb0293x ( How) do aluminium adjuvants work? cord-293559-c78wcr8m A Literature Review Is there a rationale for heparin use among severe COVID-19 patients? cord-016475-7ldxvbpz Are we ready for pandemic influenza? cord-016475-7ldxvbpz Attenuated Or Inactivated Influenza- A Virus- Vaccine Caspases: the executioners of apoptosis Protein kinases-- the major drug targets of the twenty- first century? cord-016475-7ldxvbpz GG167 Influenza Study Group Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment MAPK- regulated transcription: a continuously variable gene switch? cord-016475-7ldxvbpz In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication Novel generations of influenza vaccines Cold- adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? cord-016475-7ldxvbpz Influenza: emergence and control Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics Effective construction of DNA vaccines against variable influenza genes by homologous recombination Influenza virus induction of apoptosis by intrinsic and extrinsic mechanisms Influenza virus- induced AP-1-dependent gene expression requires activation of the JNK signaling pathway Influenza- virus- induced signaling cascades: targets for antiviral therapy? cord-016475-7ldxvbpz The influenza B virus nonstructural NS1 protein is essential for efficient viral growth and antagonizes beta interferon induction A pandemic warning? cord-272512-gevrlcvy Does this confirm trafficking of antigen- specific memory cells following exposure of the nasopharynx to transgenic alfalfa or does this suggest that vaccine antigen survived rumination and sensitized GALT by transport across the intestinal epithelium? cord-272512-gevrlcvy Is the edible format the future for veterinary vaccines in ruminanting animals? cord-272512-gevrlcvy Why vaccinate mucosally? cord-304188-1nm1tbig Papers of particular interest, published within the annual period of review, have been highlighted as: Immune stimulation systemic inflammation Safety fewer side effects? cord-303368-tzgql225 The Veterinary Immunity in the Fetus and Newborn Bovine respiratory syncytial virus infection Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in 3-week- old calves experimentally challenged with BRSV Efficacy of an intranasal modified live bovine respiratory syncytial virus and temperature- sensitive parainfluenza type 3 virus vaccine in 3-week- old calves experimentally challenged with PI3V Design effect in multicenter studies: gain or loss of power? cord-297203-f3f31h4r Replication- deficient ebolavirus as a vaccine candidate Single- dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge Virus- like particles in vaccine development Virus- like particles as particulate vaccines Formulation and stabilization of recombinant protein based virus- like particle vaccines Vaccines for the 21st century DNA vaccines: recent developments and future possibilities DNA vaccines-back in the saddle again? cord-297203-f3f31h4r The yellow fever 17D virus as a platform for new live attenuated vaccines From research to hase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine Creation of a recombinant Rift Valley fever virus with a two- segmented genome IRES dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells IRES- based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region Development of live attenuated arenavirus vaccines based on codon deoptimization Adenoviruses as vaccine vectors Pre- existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? cord-276193-cngz535o A pandemic warning? cord-276193-cngz535o improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens Designing cell lines for viral vaccine production: where do we stand? cord-301577-3qc56c7d MassTag polymerase- chain- reaction detection of respiratory pathogens, including a new rhinovirus genotype, that caused influenza- like illness in New York state during Utilization of nucleic acid amplification assays for the detection of respiratory viruses Molecular detection of viral causes of encephalitis and meningitis in New York state Real- time reverse transcription- PCR assay for comprehensive detection of human rhinoviruses Development of a genomics- based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York state Design and implementation of a protocol for the detection of Legionella in clinical and environmental samples Principles and techniques of electron microscopy: biological applications Same- day diagnostic electron microscopy of infected cell cultures by a modified protocol for conventional and microwave processing Identification of enterically transmitted hepatitis virus particles by solid phase immune electron microscopy Comparison of flavivirus universal primer pairs and development of a rapid, highly sensitive heminested reverse transcription- PCR assay for detection of flaviviruses targeted to a conserved region of the NS5 gene sequences Yellow fever outbreak, Imatong, southern Sudan Fatal multiorgan failure due to yellow fever vaccine- associated viscerotropic disease Viscerotropic disease following yellow fever vaccination in Peru Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place? cord-315131-4yb2b70g The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga- like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum Facing inward from compartment shores: How many pathways were we looking for? cord-297131-3a9vjpvn Vaccines of the future? cord-297131-3a9vjpvn Why are pharmaceutical companies gradually abandoning vaccines? cord-306733-df36w6l7 What Does Plant- Based Vaccine Technology Offer to the Fight against COVID-19? cord-307899-427a7i3h To control atrophic rhinitis, avirulent live, or inactivated organisms alone or in combination with P. multocida, Erysipelothrix rhusiopathiae and!? cord-303880-zv4nbz9p Artificial intelligence vs COVID-19: limitations, constraints and pitfalls Apple and Google's covid- tracing tech has been released to 23 countries Can mathematical modelling solve the current Covid-19 crisis? cord-330342-i55czo8a When Will You Be Able to Get a Coronavirus Vaccine? cord-322913-sq9mq6f1 Immunosenescence and inflamm- aging as two sides of the same coin: friends or foes? cord-314009-7t1bzc7f 138 7.6.1 Emulsions for template- based particle assembly 138 7.6.2 PRINT- based adjuvant production Vaccine adjuvants: current state and future trends New- age vaccine adjuvants: friend or foe? cord-266204-ipa017wz * 03-bound measles virus peptides by 2D- liquid chromatography tandem mass spectrometry Are cases of mumps in vaccinated patients attributable to mismatches in both vaccine T- cell and B- cell epitopes?: cord-266204-ipa017wz : how much can the adaptive immune system adapt? cord-266204-ipa017wz Is science leading us toward a new path of directed vaccine development and discovery? cord-266204-ipa017wz The immunogenetics of smallpox vaccination Genetic basis for adverse events after smallpox vaccination Identification of fever and vaccine- associated gene interaction networks using ontology- based literature mining Common variants associated with general and MMR vaccine- related febrile seizures The clinician's guide to the anti- vaccinationists'galaxy Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti- vaccine and consumer culture and vaccinomics Understanding those who do not understand: a brief review of the anti- vaccine movement Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics Cell culture- based influenza vaccines: A necessary and indispensable investment for the future Ebola virus vaccines: where do we stand? cord-266204-ipa017wz We have asked the question, as have other scientists,''does it make sense in the 21st century to give the same vaccine, dose, and at the same frequency to everyone, regardless of age, weight, gender, race, genotype, and medical condition? |
| cord-282246-wyanwvxa | Are there other inflammasome sensors of RV or other enteric viruses? |
| cord-282246-wyanwvxa | Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? |
| cord-282246-wyanwvxa | What is the physiological relevance of these s sensors in the human intestine? |
| cord-282246-wyanwvxa | coordinate in the cytoplasm? |
| cord-316534-ep7ezoko | The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? |
| cord-322955-7dw32xby | Evaluation of COVID-19 RT- qPCR test in multi- sample pools Role of Chest CT in Diagnosis and Management COVID-19)? |
| cord-324911-6s7ubbxl | Alongside these efforts, the UK Chief Medical Officer for the Department of Health and Social Care( DHSC), Dame Sally Davies, raised the question to government and related stakeholders-what could the UK do to be better prepared for future outbreaks of infectious diseases? |
| cord-275033-y9z9l0ji | Definition of Policy What is Policy? |
| cord-275033-y9z9l0ji | Did Children Receive DTaP Vaccinations Earlier after Accelerated DTaP Immunization Recommendations by Local Public Health during 2003 Pertussis Outbreaks in Oregon?: |
| cord-275033-y9z9l0ji | States? |
| cord-275033-y9z9l0ji | The National Vaccine Advisory Committee The president's child immunization initiative-- a summary of the problem and the response Effectiveness of a practice- based intervention to increase vaccination rates and reduce missed opportunities? |
| cord-324001-m7ys95z7 | influenza viruses in ferrets and mice Influenza A(H1N1)v in the Southern Hemisphere- lessons to learn for Europe? |
| cord-285883-rlliacex | Are Ad- based vaccines targeting the spike and capsid proteins our best bet? |
| cord-285883-rlliacex | Is it possible that Ad- specific T reg s could prevent lysis of vaccine- infected cells and allow long- term expression of SARS- CoV-2 antigens? |
| cord-285883-rlliacex | Should we go"all in"on an Ad- based vaccine against SARS- CoV-2? |
| cord-285883-rlliacex | Why are mucosal homing anti- Ad T EM s important? |
| cord-294789-07hto8qn | People will judge a COVID-19 vaccination campaign's integrity not simply on biomedical merits, but on matters of fairness and equity- that is, have people received their just portion of health services, and has disease prevention, ultimately, been fairly distributed? |
| cord-294789-07hto8qn | Will Ebola change the game? |
| cord-328557-f6o1aynz | COVID-19: What is next for public health? |
| cord-274264-s477tw3x | How effective would the vaccine need to be to suppress the pandemic? |
| cord-274264-s477tw3x | The Lancet What Is Required to Prevent a Second Major Outbreak of SARS- CoV-2 upon Lifting Quarantine in Wuhan City Assessing the effects of metropolitan- wide quarantine on the spread of COVID-19 in public space and households Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China Can self- imposed prevention measures mitigate the COVID-19 epidemic Will an imperfect vaccine curtail the COVID-19 pandemic in the US? |
| cord-274264-s477tw3x | What proportion of the population would need to be vaccinated? |
| cord-274264-s477tw3x | and( 3) What levels of social distancing measures and face mask use would need to be maintained in the context of different values of vaccine effectiveness and coverage? |
| cord-274264-s477tw3x | medRxiv Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? |
| cord-296839-b6bm8do1 | Oslo, Norway gunnstein.norheim@cepi.net Travel, migrationand emerging infectious diseases Institute for Disease Modeling? |
| cord-296839-b6bm8do1 | Why are n't we worried about the next epidemic? |
| cord-296839-b6bm8do1 | a retrospective study UnderstandingEbola: the 2014 epidemic ZikavirusandpregnancyinBrazil: whathappened? |
| cord-315570-khm1veuv | How Far From Clinical Use? |
| cord-258353-uw8padla | Could I share a few things I've learned about vaccine safety with you? |
| cord-258353-uw8padla | How should physicians proceed? |
| cord-258353-uw8padla | Paediatr Child Health( Oxford) Is physician dismissal of vaccine refusers an acceptable practice in Canada? |
| cord-258353-uw8padla | Some physicians began the conversation with what the authors called a participatory approach, offering parents latitude over vaccination decisions with opening lines such as:"What do you think about doing some shots today? |
| cord-258353-uw8padla | What would it look like to increase vaccine confidence, one visit at a time? |
| cord-258353-uw8padla | When is it permissible to dismiss a family who refuses vaccines? |
| cord-258353-uw8padla | Who Later Accepts and Why? |
| cord-258353-uw8padla | Who else is better positioned to do so than the pediatricians who form long- term relationships with parents and their children? |
| cord-325010-7qrht7uq | Perhaps commonsense can prevail? |
| cord-340900-f2iuy9e1 | Should scientists infect healthy people with the coronavirus to test vaccines? |
| cord-313911-lfn9ggg3 | Smallpox vaccination: risk considerations for patients with atopic dermatitis Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines Identification of murine poxvirus- specific CD8+ CTL epitopes with distinct functional profiles Profiling the humoral immune response to infection by using proteome microarrays: high- throughput vaccine and diagnostic antigen discovery Smallpox vaccine- induced antibodies are necessary and sufficient for protection against monkeypox virus smallpox vaccinations: how much protection remains? |
| cord-313911-lfn9ggg3 | The future of smallpox vaccination: is MVA the key? |
| cord-004435-l66ost6q | 2020:9 Time for T? |
| cord-004435-l66ost6q | An update and perspective Progress and challenges in TB vaccine development Vaccines for the elderly: current use and future challenges Remembrance of things past: long- term B cell memory after infection and vaccination Global practices of meningococcal vaccine use and impact on invasive disease New vaccine technologies to combat outbreak situations What are the most powerful immunogen design vaccine strategies? |
| cord-004435-l66ost6q | Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges Evaluation of levamisole as an adjuvant for typhoid fever vaccine formulation HLA and infectious diseases Predicting antigen presentation- what could we learn from a million peptides? |
| cord-004435-l66ost6q | How does the VSG coat of bloodstream form African trypanosomes interact with external proteins? |
| cord-004435-l66ost6q | The use of databases, data mining and immunoinformatics in vaccinology: where are we? |
| cord-004435-l66ost6q | Vaccines( Basel) Recalling the future: immunological memory toward unpredictable influenza viruses Human leukocyte antigen( HLA)-binding epitopes dataset for the newly identified T- cell antigens of Mycobacterium immunogenum Fundamentals and methods for T- and B- cell epitope prediction Human Leukocyte Antigen( HLA) and immune regulation: how do classical and non- classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections? |
| cord-004435-l66ost6q | and what are the potential clinical implications? |
| cord-004435-l66ost6q | faster de novo structure prediction for linear peptides in solution and in complex The Protein Model Portal- a comprehensive resource for protein structure and model information Exploring Leishmania secretory proteins to design B and T cell multi- epitope subunit vaccine using immunoinformatics approach AP-1 transcription factors as regulators of immune responses in cancer Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? |
| cord-324219-z1nigtb5 | have we learned? |
| cord-336730-hqgwj8vs | Young cats are especially prone: 54% of all FIP cases affected cats younger than 12 months of age and 70% cats younger than 4 year?. |
| cord-309083-ew9cwiw0 | An etiological study on mass mortality of cultured colorcarp juveniles showing edema A survey of koi herpesvirus and carp edema virus in colorcarp cultured in Niigata Prefecture Situation and tendency of the fishery vaccine development A herpesvirus associated with mass mortality of juvenile and adult koi, a strain of common carp Current knowledge on koi herpesvirus( KHV): a review KHV, CNGV or CyHV-3, which is the koi/ carp killer? |
| cord-309083-ew9cwiw0 | Another potential carp killer? |
| cord-309083-ew9cwiw0 | Do wild fish species contribute to the transmission of koi herpesvirus to carp in hatchery ponds? |
| cord-309083-ew9cwiw0 | What happens to the DNA vaccine in fish? |
| cord-318272-spt0oea0 | CAF01, promotes long- lived Mycobacterium tuberculosis- specific T- cell responses in human A triple co- culture model of the human respiratory tract to study immune- modulatory effects of liposomes and virosomes The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1 Immune responses induced by nano- self- assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein Cubosomes: the next generation of smart lipid nanoparticles? |
| cord-318272-spt0oea0 | In vivo gold nanoparticle delivery of peptide vaccine induces anti- tumor immune response in prophylactic and therapeutic tumor models Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo Multicopy multivalent'glycopolymer- stabilized gold nanoparticles as potential synthetic cancer vaccines Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant Single- walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor- associated antigens Immunisation of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein Silica vesicle nanovaccine formulations stimulate long- term immune responses to the bovine viral diarrhoea virus E2 protein Lipopeptide- coated iron oxide nanoparticles as potential glycoconjugate- based synthetic anticancer vaccines A visible codelivery nanovaccine of antigen and adjuvant with self- carrier for cancer immunotherapy Effect of preexisting neutralizing antibodies on the anti- tumor immune response induced by chimeric human papillomavirus virus- like particle vaccines Room temperature stable PSPA- based nanovaccine induces protective immunity Reversal of autoimmunity by boosting memory- like autoregulatory T cells Peptide- MHC- based nanovaccines for the treatment of autoimmunity: a"one size fits all"approach? |
| cord-340516-9dfaqsv7 | ( COVID-19) Enteric involvement of coronaviruses: is faecal- oral transmission of SARS- CoV-2 possible? |
| cord-325141-x3txhjkr | Based on this information, how likely are you to take the COVID-19 vaccine? |
| cord-325141-x3txhjkr | Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe Pandemic Public Health Paradox Media Attention, Risk Perception and Public Reactions in 5 European Countries When a COVID-19 vaccine is ready, will we all be ready for it? |
| cord-326614-cik3ino6 | : Are they good adjuvants? |
| cord-326614-cik3ino6 | What Are Clinical Trials and Studies? |
| cord-335960-biwnqa3f | An outbreak of measles at an international sporting event with airborne transmission in a domed stadium Influenza vaccination for athletes? |
| cord-335960-biwnqa3f | The infectious complications of anabolic- androgenic steroid injection Active and passive immunization A statewide survey of immunization rates in Minnesota school age children: implications for targeted assessment and prevention strategies Swanson's family practice review: a problem- oriented approach Evaluation of a two- dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes Antibody response of pneumococcal vaccine: need for booster dosing? |
| cord-316893-jwjr67po | Can vaccination coverage be improved by reducing missed opportunities for vaccination? |
| cord-316893-jwjr67po | How can we design vaccines to have optimal programmatic impact? |
| cord-316893-jwjr67po | a qualitative exploration of barriers and facilitators to child and adult immunisation uptake among Gypsies, Travellers and Roma Immunization divide: who do get vaccinated in Bangladesh? |
| cord-342831-4qfe8kok | The safety of chitosan as a pharmaceutical excipient Chitosan- based drug nanocarriers: where do we stand? |
| cord-325966-0g7a9s5z | A narrative review COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-325966-0g7a9s5z | Can we use interleukin-6( IL-6) blockade for coronavirus disease 2019( COVID-19)-induced cytokine release syndrome( CRS)? |
| cord-016594-lj0us1dq | Are high- scoring matches an artefact or are they real and meaningful? |
| cord-016594-lj0us1dq | But, is this practically useful for selecting candidate vaccines? |
| cord-016594-lj0us1dq | Have we cut ourselves too short in mapping CTL epitopes? |
| cord-016594-lj0us1dq | However, and say that we were offered a newly sequenced pathogen genome, is such a classification for AB toxins helpful when trying to identify a potential exotoxins? |
| cord-016594-lj0us1dq | The same old, familiar caveats apply here: are chosen thresholds appropriate? |
| cord-016594-lj0us1dq | This typically yields exact values for, say, the binding affinity of a peptide to a protein component of the immune system, or an unequivocal yes or no answer to the question: is this peptide sequence an epitope? |
| cord-016594-lj0us1dq | Using NERVE, the prioritisation of potential candidate antigens consists of several stages: prediction of subcellular localisation; is the antigen an adhesion?; identification of membrane- crossing domains; and comparison to pathogen and human proteomes. |
| cord-016594-lj0us1dq | Why should this be? |
| cord-016594-lj0us1dq | Why should this be? |
| cord-325300-wawui0fd | What is a reasonable explanation of the occurrence; is there a previous pattern, with the present episode a recurrence or new event? |
| cord-325300-wawui0fd | What steps are needed to prevent spread and recurrence of the disease? |
| cord-343421-k1dqe4lk | Typhi live vector vaccines finally come of age Pre- existing immunity against vaccine vectors- friend or foe? |
| cord-032017-h0cj4izx | How much avoidable risk to a child is too much to ignore? |
| cord-032017-h0cj4izx | If the imminent danger argument were reasonable, then how does one explain required car seats for children? |
| cord-032017-h0cj4izx | Is it fair for an individual's rejection of established scientific evidence to place their child and other people at risk in the name of personal freedom or preference? |
| cord-032017-h0cj4izx | Is it fair to ask others to accept the human suffering and financial burden resulting from infections that could easily have been prevented? |
| cord-032017-h0cj4izx | No doubt the looming certainty of death from untreated leukemia makes it easier for the authorities to summon the courage to act, but is there an acceptable threshold for allowing a preventable risk? |
| cord-032017-h0cj4izx | So why are parents allowed to forbid the administration of life- saving vaccines or vitamin K but not allowed to deny cancer chemotherapy? |
| cord-032017-h0cj4izx | The bottom- line question is"Does the potential benefit of an immunization exceed the likelihood of an adverse effect?" |
| cord-032017-h0cj4izx | Was this child abuse? |
| cord-032017-h0cj4izx | Why are vaccines not viewed in a similar fashion? |
| cord-032017-h0cj4izx | Why? |
| cord-018811-zhwr3h07 | But what then? |
| cord-018811-zhwr3h07 | But why did some die and exactly how were they killed by such a minute and fragile form of life that we know as the orthomyxovirus influenza? |
| cord-018811-zhwr3h07 | Could it be a Gram- negative bacterium such as H. influenzae, already described by Pfeiffer as the cause of the previous influenza pandemic of 1889? |
| cord-018811-zhwr3h07 | Gauguin in his last great painting"Who are we, where have we come from, where are we going?"asks crucial questions about the future of humankind. |
| cord-018811-zhwr3h07 | Or could it be a virus? |
| cord-018811-zhwr3h07 | These internally situated proteins are certainly immunogenic( particular NP) but could the immunity induced, either T cell or antibody, be broadly reacting? |
| cord-018811-zhwr3h07 | Twenty- First Century Vaccines Induce Protection Across the Different Virus Subtypes? |
| cord-018811-zhwr3h07 | Was the immune reaction and ensuing cytokine storm overwhelming or was virus replication in the endothelial cells of the air sacs more important? |
| cord-018811-zhwr3h07 | Why not create a reassortant in the laboratory with six replicative genes of A/ PR/8/34 to give high replication while having the two new HA and neuraminidase( NA) genes of the new epidemic virus? |
| cord-318983-rmvqf6s9 | How, then, do we get the right vaccine to the right person? |
| cord-318983-rmvqf6s9 | When Is Discrimination Wrong? |
| cord-340042-intxyu46 | Structural basis of receptor recognition by SARS- CoV-2 Vaccination against Toxoplasma gondii: an increasing priority for collaborative research? |
| cord-330496-p3o6zkhf | Vaccine Prevention of feline injection- site sarcomas: Is there a scientific foundation for vaccine recommendations at this time? |
| cord-289763-jek2pd31 | If not sure: What makes you unsure whether you will get the vaccine?Open ended What is your best guess as to whether you will get the coronavirus within the next 6 months? |
| cord-289763-jek2pd31 | Intent to be vaccinated against COVID-19 was measured with the question, “ When a vaccine for the coronavirus becomes available, will you get vaccinated? ” |
| cord-289763-jek2pd31 | Participants who responded"no"or"not sure"were asked one of the following open- ended questions, respectively:"What makes you unwilling to get the vaccine?"or"What makes you unsure whether you will get the vaccine?." |
| cord-289763-jek2pd31 | Participants who responded"no"or"not sure"were asked one of the following open- ended questions, respectively:"What makes you unwilling to get the vaccine?"or"What makes you unsure whether you will get the vaccine?." |
| cord-289763-jek2pd31 | To assess perceived risks of infection, we asked,"What is your best guess as to whether you will get the coronavirus within the next 6 months?"; response options were"I do n't think I will get the coronavirus,""I think I will get a mild case of the coronavirus,""I think I will get seriously ill from the coronavirus,"or"I have already had the coronavirus." |
| cord-289763-jek2pd31 | We assessed intent to be vaccinated for the novel coronavirus with the question,"When a vaccine for the coronavirus becomes available, will you get vaccinated?"followed by the response options"yes,""no,"and"not sure." |
| cord-328935-mn8r972x | First, why is the systemic response to the LPG/ protein complex skewed toward IgG1( a Th2 response in cattle) and not IgG2( a Th1 response)? |
| cord-328935-mn8r972x | Second, are IgG or IgA antibodies to the LPG- containing antigen most protective and how can that Ig isotype be enriched to enhance protection? |
| cord-344576-upsc9cf8 | The global spread of Zika virus: is public and media concern justified in regions currently unaffected? |
| cord-344576-upsc9cf8 | WHO Concern over Zika virus grips the world WHO Director- General summarizes the outcome of the Emergency Committee regarding clusters of microcephaly and Guillain- Barré syndrome Zika virus, what CDC is doing? |
| cord-279026-s3yx62u6 | Are there changes in the carrier through the incorporation of new foreign genes? |
| cord-279026-s3yx62u6 | Are there changes in the tissue tropism of the virus? |
| cord-279026-s3yx62u6 | First, is the effect consistent? |
| cord-279026-s3yx62u6 | Is there exchange of genetic information with other wild type or vaccine strains of the carrier? |
| cord-279026-s3yx62u6 | Is there reversion to virulence through the incorporation of complementation genes? |
| cord-279026-s3yx62u6 | Second, is the effect specific? |
| cord-279026-s3yx62u6 | Will the carrier spread unwanted genes such as antibiotic resistance into the environment? |
| cord-340994-m7vazpq9 | Clinical prevention and population health: curriculum framework for health professions Prevention for the 21st century: setting the context through undergraduate medical education Improvement in vaccination knowledge among health students following an integrated extra curricular intervention, an explorative study in the University of Palermo Improvement in attitudes toward influenza vaccination in medical students following an integrated curricular intervention Mandatory influenza vaccination of health care workers: translating policy to practice Missed opportunities? |
| cord-340994-m7vazpq9 | What should we do about vaccine hesitancy? |
| cord-023853-y5g4ceq9 | Can we build a better mousetrap? |
| cord-023853-y5g4ceq9 | Development will be led by developing countries when they are enabled to plan ahead; What factors account for the disparity in immunization coverage between developed and less developed countries? |
| cord-023853-y5g4ceq9 | How does its mission compare with those of Global Immunization Vision Strategy What major barriers confront the GAVI Alliance and GIVS in their efforts to ensure equity in access to new and underused vaccines in developed and less developed countries? |
| cord-023853-y5g4ceq9 | How successful are IFFMs and AMCs in accomplishing their mission? |
| cord-023853-y5g4ceq9 | How will the poorest countries reach this point? |
| cord-023853-y5g4ceq9 | What are the major barriers? |
| cord-023853-y5g4ceq9 | What is the GAVI Alliance? |
| cord-023853-y5g4ceq9 | What should be the priorities for future vaccine research and development globally? |
| cord-023853-y5g4ceq9 | Which Vaccines for the Future? |
| cord-344062-8xxu0orq | Hayrunnisa Bekis Bozkurt https://orcid.org/0000-0001-8642-4872 Clinical features in pediatric COV- ID-19 Are children less susceptible to COVID-19? |
| cord-344062-8xxu0orq | cord-344062- 8xxu0orq authors: Bozkurt, Hayrunnisa Bekis title: Is the impact of childhood vaccines on coronavirus disease 2019, which is moderate in pediatric patients, possible? |
| cord-345689-5ns1onkw | How to manipulate these pathogens that are highly pathogenic, in large quantities? |
| cord-355906-yeaw9nr8 | Case series from a tertiary care hospital in Sri Lanka Breast milk as a possible route of vertical transmission of dengue virus? |
| cord-008716-38sqkh9m | Are there immunological consequences of passive immunoprophylaxis? |
| cord-008716-38sqkh9m | Cytotoxic T- cell immunity to influenza Does prematurity alter the course of respiratory syncytial virus infection? |
| cord-008716-38sqkh9m | Given these experiences, could we expect another new strain to behave differently today? |
| cord-008716-38sqkh9m | Negative- strand virus M and retrovirus MA proteins: all in a family? |
| cord-008716-38sqkh9m | Prevalence of various respiratory viruses in the middle ear during acute otitis media A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion Recovery of a new agent from patients with acute respiratory disease Characterization of the influenza A virus gene pool in avian species in southern China: was H6N1 a derivative or a precursor of H5N1? |
| cord-008716-38sqkh9m | The IMpact- RSV Study Group Molecular characterization of H9N2 influenza viruses: were they the donors of the'internal'genes of H5N1 viruses in Hong Kong? |
| cord-008716-38sqkh9m | What are our options for vaccination against potentially pandemic viruses? |
| cord-008716-38sqkh9m | What are the general principles underlying vaccine development for these viruses? |
| cord-008716-38sqkh9m | What are the viruses with pandemic potential? |
| cord-008716-38sqkh9m | What quantity of antiviral drugs is available for emergency use? |
| cord-008716-38sqkh9m | Which vaccines are available? |
| cord-337577-dqikrmk7 | A meta- analysis Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children Tetanus toxoid immunization to reduce mortality from neonatal tetanus Antibody responses to envelope glycoproteins in HIV-1 infection Where does HIV hide? |
| cord-337577-dqikrmk7 | What level of hepatitis B antibody is protective? |
| cord-337577-dqikrmk7 | where do we stand? |
| cord-269623-9pxdeva3 | Does influenza vaccination prevent asthma exacerbations in children? |
| cord-269623-9pxdeva3 | Is this a sign that I really did become a better doctor or is it a symptom of ageing? |
| cord-269623-9pxdeva3 | Learning from experience? |
| cord-269623-9pxdeva3 | Lethal H5N1 influenza viruses escape host anti- viral cytokine responses Induction of proinflammatory cytokines in human macrophages by influenza A( H5N1) viruses: a mechanism for the unusual severity of human disease? |
| cord-269623-9pxdeva3 | The efficacy of influenza vaccine in elderly persons: a meta- analysis and review of the literature Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease Is immunizing all patients with chronic lung disease in the community against influenza cost- effective? |
| cord-269623-9pxdeva3 | Were my early errors more influential on my subsequent practice or are my current errors not recognised or not made known to me by sympathetic colleagues? |
| cord-269623-9pxdeva3 | were they the donors of the''internal''genes of H5N1 viruses in Hong Kong? |
| cord-344669-hw57silv | The cervical cancer epidemic that screening has prevented in the UK Human papillomavirus infections and risks of cervical cancer: what do women know? |
| cord-344669-hw57silv | Why do parents decide against immunization? |
| cord-339726-eg0hajzl | Science Magazine Ethical comparators in coronavirus vaccine trials Human challenge studies to accelerate coronavirus vaccine licensure Responding to Covid-19-A once- in- a- century pandemic? |
| cord-339726-eg0hajzl | The time course of the immune response to experimental coronavirus infection of man Speed coronavirus vaccine testing by deliberately infecting volunteers? |
| cord-344006-0iq9s94n | In patients of COVID-19, what are the symptoms and clinical features of mild and moderate cases? |
| cord-344006-0iq9s94n | what next? |
| cord-353730-owcapg8h | inhibition of antibody but not T cell responses allows successful early prime- boost strategies in mice Efficacy of inactivated poliovirus vaccine in India Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor( CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines How to predict the immune status of poliovirus vaccinees? |
| cord-326960-9phlylce | H1N1 influenza: What have we learned? |
| cord-326960-9phlylce | vu all over again? |
| cord-355618-7kfxc2w1 | How and why does this hesitancy shift from physician- guided acceptance of vaccines to their refusal? |
| cord-355618-7kfxc2w1 | With several vaccine candidates already being tested in clinical trials, we pose the question: what will the vaccine hesitant do in the face of this pandemic? |
| cord-328698-eeg1k5a6 | Have you ever postponed a vaccine recommended by a physician because of doubts about it? |
| cord-328698-eeg1k5a6 | Once we have it, will we use it? |
| cord-328698-eeg1k5a6 | We evaluated participants'self- reported vaccine hesitancy according to the WHO definition using three previously adapted questions:"Have you ever refused a vaccine for yourself or a child because you considered it as useless or dangerous?" |
| cord-303674-0xo2fiop | + bacteria by M cells initiates mucosal immune response Green therapeutic biocapsules: using plant cells to orally deliver biopharmaceuticals Transgenic plants: a 5-year update on oral antipathogen vaccine development Plant- based vaccines against viruses Preclinical and clinical development of plant- made virus- like particle vaccine against avian H5N1 influenza Food- grade organisms as vaccine biofactories and oral delivery vehicles Plant- made oral vaccines against human infectious diseases- are we there yet? |
| cord-303674-0xo2fiop | -lymphocytes, dendritic cells or keratinocytes? |
| cord-303674-0xo2fiop | Chimeric antigen receptor( CAR)-redirected T cells: is there a place for them in infectious diseases? |
| cord-303674-0xo2fiop | Intradermal vaccine delivery: will new delivery systems transform vaccine administration? |
| cord-303674-0xo2fiop | Need of cost- effective vaccines in developing countries: what plant biotechnology can offer? |
| cord-303674-0xo2fiop | The increasing value of plant- made proteins Plant- produced vaccines: promise and reality Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta- TC6 cells Disease prevention: an opportunity to expand edible plant- based vaccines? |
| cord-274756-nnm1n09a | Innate lymphoid cells- how did we miss them? |
| cord-274756-nnm1n09a | The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: Implications for cancer therapy Natural killer cells in cancer immunotherapy Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? |
| cord-274756-nnm1n09a | What are the mechanisms that lead to a break in tolerance? |
| cord-274756-nnm1n09a | Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? |
| cord-274756-nnm1n09a | causes and conversion CTLA-4/ CD80 pathway regulates T cell infiltration into pancreatic cancer Molecular interactions of antibody drugs targeting PD-1, PD- L1, and CTLA-4 in immuno- oncology Immunosenescence and its hallmarks: how to oppose aging strategically? |
| cord-274756-nnm1n09a | how"lytic"must they be for therapeutic efficacy? |
| cord-274756-nnm1n09a | plasticity in human autoimmune arthritis is driven by the inflammatory environment Harnessing the plasticity of CD4+ T cells to treat immune- mediated disease Immunological memory: what's in a name? |
| cord-014462-11ggaqf1 | Both ATP and GTP were utilized as phosporyl donors and Mn 2? |
| cord-014462-11ggaqf1 | Cut off was calculated as Mean negative control? |
| cord-014462-11ggaqf1 | FMDV P1- 3CD''O''vaccine gene constructs in pCDNA3.1? entrapped by the nanoparticles was prepared by using different molarity of calcium chloride and disodium hydrogen orthophosphate. |
| cord-014462-11ggaqf1 | Helicase activity of NSs was absolutely dependent on ATP and Mg 2? |
| cord-014462-11ggaqf1 | How do Indian journals perform in Maintaining quality? |
| cord-014462-11ggaqf1 | How do motivate the scientists to improve their scientific output? |
| cord-014462-11ggaqf1 | How to motivate the scientists to improve their scientific output? |
| cord-014462-11ggaqf1 | In this regard, rNSs is a unique enzyme which does not have the canonical helicase motifs but can catalyze dsDNA/ dsRNA unwinding in an ATP and Mg 2? |
| cord-014462-11ggaqf1 | Should we compare the growth of Indian science with other developed countries? |
| cord-014462-11ggaqf1 | What ails Indian Science? |
| cord-014462-11ggaqf1 | What criteria should be adopted to judge the quality and standard of scientific research? |
| cord-319226-yvgvyif0 | Toolkits A Psychological perspective on economic Biased assimilation and attitude polarization: The effects of prior theories on subsequently considered evidence Changes in suicide rates following media reports on celebrity suicide: A meta- analysis Mass killings in the United States from 2006 to 2013: Social contagion or random clusters? |
| cord-319226-yvgvyif0 | Who is responsible for the failure to vaccinate? |
| cord-319226-yvgvyif0 | Will it be mandatory? |
| cord-319226-yvgvyif0 | Will there be penalties for non- compliance? |
| cord-348283-7xorq5ce | Can we contain the COVID-19 outbreak with the same measures as for SARS? |
| cord-348283-7xorq5ce | Does urbanization make emergence of zoonosis more likely? |
| cord-343347-guciupc8 | Efficacy or effectiveness? |
| cord-343347-guciupc8 | In 2010, Weinberg and Szilagyl eloquently approached the issues of efficacy and effectiveness clarifying the road to correctly answer the relevant but complex question:"How well does the candidate vaccine prevent the disease for which it was developed? |
| cord-343347-guciupc8 | The aging innate immune system Reduction in acute gastroenteritis hospitalizations among us children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? |
| cord-315339-dcui85lw | : is it infectious? |
| cord-315339-dcui85lw | In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract Cytotoxic T lymphocyte memory: role in cross- protective immunity against influenza? |
| cord-315339-dcui85lw | N- trimethyl chitosan( TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model Incidence of acute respiratory illnesses among enlisted service members during their first year of military service: did the 2011 resumption of adenovirus vaccination of basic trainees have an effect? |
| cord-315339-dcui85lw | The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines Orthomyxoviruses M cell- targeted DNA vaccination Pathogen recognition and development of particulate vaccines: does size matter? |
| cord-315339-dcui85lw | modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine Induction of proinflammatory cytokines in human macrophages by influenza A( H5N1) viruses: a mechanism for the unusual severity of human disease? |
| cord-275031-0y0d4brz | As for the alternative solutions, web cartoonist and ex- NASA roboticist Randall Munroe, furnishing"serious scientific answers to absurd hypothetical questions"via his"What if?"blog[ 13], has addressed the issue if common cold( i.e. rhinoviruses) could be eradicated by all individuals of the planet keeping the maximal possible distance from each other( i.e. about 77 m) for a couple of weeks. |
| cord-275031-0y0d4brz | Did you expect them? |
| cord-275031-0y0d4brz | Do you have a personal motto, quote or leading sentence? |
| cord-275031-0y0d4brz | How will the project go on? |
| cord-275031-0y0d4brz | What advice would you give to the young next- generation scientists? |
| cord-275031-0y0d4brz | What if? |
| cord-275031-0y0d4brz | What is the take- home message of the article? |
| cord-275031-0y0d4brz | What was your first reaction when you faced the results? |
| cord-304472-mi5v6512 | A 12-month- interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response Paediatric Dengue Fever diagnosed through parents'epidemiologic report and preventive strategy during the acute phase of infection Dengue in peace corps volunteers Travel vaccine preventable diseases- updated logarithmic scale with monthly incidence rates What proportion of international travellers acquire a travel- related illness? |
| cord-304472-mi5v6512 | Mosquito repellents for the traveller: does picaridin provide longer protection than DEET? |
| cord-304472-mi5v6512 | So what about combining both vaccines in a heterologous prime- boost regimen, leveraging upon the benefits of each vaccine and thereby minimizing safety concerns? |
| cord-304472-mi5v6512 | What is the prospect of a safe and effective dengue vaccine for travellers? |
| cord-304472-mi5v6512 | Would sequential immunization induce stronger and broader immunity against four DENV serotypes than tetravalent- formulated immunization and overcome the viral interference we have seen to date for the live attenuated dengue vaccine formulations? |
| cord-304472-mi5v6512 | preand post- travel advice and clinical management A: Can dengue virus be sexually transmitted? |
| cord-354068-4qlk6y7h | A hitherto unknown infectious disease contracted from monkeys Filoviridae: A taxonomic home for marburg and ebola viruses? |
| cord-354068-4qlk6y7h | Recombinant human activated protein c for the postexposure treatment of ebola hemorrhagic fever Marburg and ebola hemorrhagic fevers: Does the primary course of infection depend on the accessibility of organ- specific macrophages? |
| cord-342819-p8wp6yvo | 33 Need for adjuvants? |
| cord-342819-p8wp6yvo | A potential solution for emerging pathogens and biodefense? |
| cord-342819-p8wp6yvo | How many epitopes? |
| cord-342819-p8wp6yvo | What happened and what lessons can we learn? |
| cord-345191-nabxpyw3 | A European 619 survey on willingness to be vaccinated against COVID-19 Determinants of COVID-19 Vaccine 622 Acceptance in the Willingness to vaccinate against COVID-19 in Australia More vaccines for children? |
| cord-345191-nabxpyw3 | The push for a COVID-19 vaccine Millions could be vaccinated against COVID-19 as UK secures strong 606 portfolio of promising vaccines Ensuring global access to COVID-19 vaccines JCVI: updated interim advice on priority groups for COVID-19 610 vaccination Using thematic analysis in psychology Parents'and guardians'views on the acceptability of a future COVID-19 vaccine: a multi Sabat, I, Once we have it, will we use it? |
| cord-345191-nabxpyw3 | would you accept the vaccine for your child/ children?". |
| cord-294366-swwz4kzd | Anamnestic response to administration of purified non- adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with longterm non- protective antibody titres The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine( 7VPnC) concurrently administered with a combination DTaP- IPV- Hib vaccine Vaccines in the public eye Preparing for the Next Pandemic WHO's attempts to eradicate polio are thwarted in Africa and Asia Spread of vaccinederived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine Long- term excretion of vaccine- derived poliovirus by a healthy child Bacillus Calmette- Guerin shares with virulent Mycobacterium tuberculosis the capacity to subvert monocyte differentiation into dendritic cell: implication for its efficacy as a vaccine preventing tuberculosis Autophagy is a defense mechanism inhibiting BCG and mycobacterium tuberculosis survival in infected macrophages BCG- different strains, different vaccines? |
| cord-294366-swwz4kzd | And can new and refined approaches succeed where more conventional approaches appear to have failed? |
| cord-294366-swwz4kzd | Can successful vaccines teach us how to induce efficient protective immune responses? |
| cord-294366-swwz4kzd | In this complex but increasingly focussed environment of vaccine development, are there opportunities for new solutions for vaccine design? |
| cord-294366-swwz4kzd | The key question addressed here is, with all our research and understanding, have we reached a new echelon in vaccine development, that of rational design? |
| cord-264814-v4wnmg03 | Antigenspecific human T- cell responses and T cell- dependent production of human antibodies in a humanized mouse model A mouse model of SARS- CoV-2 infection and pathogenesis Adaptation of SARS- CoV-2 in BALB/ c mice for testing vaccine efficacy Vaccine adjuvants: smart components to boost the immune system Correlates of adjuvanticity: a review on adjuvants in licensed vaccines Potential adjuvants for the development of a SARS- CoV-2 vaccine based on experimental results from similar coronaviruses Development of SARS- CoV-2 vaccines: should we focus on mucosal immunity? |
| cord-264814-v4wnmg03 | Available online at A single- dose live- attenuated YF17D- vectored SARS- CoV2 vaccine candidate DNA vaccines- how far from clinical use? |
| cord-264814-v4wnmg03 | COVID-19: are neutralizing antibodies neutralizing enough? |
| cord-264814-v4wnmg03 | Is BCG vaccination causally related to reduced COVID-19 mortality? |
| cord-264814-v4wnmg03 | Protection or Hyper- Activation? |
| cord-264814-v4wnmg03 | T Cell Adaptive Immunity: Protection, Immune Suppression or Disease Enhancement? |
| cord-264814-v4wnmg03 | The Spread of COVID-19 and the BCG Vaccine: a Natural Experiment in Reunified Germany SARS- CoV-2 rates in BCGvaccinated and unvaccinated young adults BCG- induced trained immunity: can it offer protection against COVID-19? |
| cord-264814-v4wnmg03 | With Task Force Vaccine Safety Expert A controlled human infection model of group a streptococcus pharyngitis: which strain and why? |
| cord-264814-v4wnmg03 | a six- year follow- up study Recovery from the middle east respiratory syndrome is associated with antibody and T- cell responses Immune cell profiling of COVID-19 patients in the recovery stage by single- cell sequencing Immunology of COVID-19: current state of the science Molecular basis of coronavirus virulence and vaccine development SARS vaccines: where are we? |
| cord-264814-v4wnmg03 | how first exposure shapes lifelong anti- influenza virus immune responses Original antigenic sin and respiratory syncytial virus vaccines What about the original antigenic sin of the humans versus SARS- CoV-2? |
| cord-264814-v4wnmg03 | mSphere Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? |
| cord-339152-wfakzb6w | : where are we? |
| cord-339152-wfakzb6w | COVID-19 Trained innate immunity not always amicable Scores of coronavirus vaccines are in competition-how will scientists choose the best? |
| cord-339152-wfakzb6w | Covid-19: what do we know so far about a vaccine? |
| cord-339152-wfakzb6w | How severe and prevalent are Ebola and Marburg viruses? |
| cord-344162-8gbe6qo7 | if a new coronavirus vaccine became available, would you accept the vaccine if it meant protecting friends, family, or at- risk groups? |
| cord-344162-8gbe6qo7 | A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large- scale retrospective temporal modelling study How well do people report time spent on Facebook? |
| cord-344162-8gbe6qo7 | Each Respondents were asked about their intent to receive a COVID-19 vaccine to protect themselves and, to explore altruistic behaviours, to protect others:"If a new coronavirus vaccine became available, would you accept the vaccine for yourself?" |
| cord-355541-5sctqkwr | How, when and where is the efficacy of the different vaccines to be evaluated? |
| cord-355541-5sctqkwr | Neutralizing antibody- independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations HIV-1 neutralizing antibodies: how full is the bottle? |
| cord-355541-5sctqkwr | WHO The global alliance for vaccines and immunization: a millennial challenge Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? |
| cord-302222-9ad0fw6z | An interesting question is: who will pay for vaccination of feedlot cattle? |
| cord-302222-9ad0fw6z | Is the economic benefit there for the meat industry, and will vaccination reduce the cost of other preventive measures and testing or will vaccine costs simply be on top of other costs? |
| cord-302222-9ad0fw6z | One health: the importance of companion animal vector- borne diseases Arthropod- borne infectious diseases of the dog and cat Zoonoses Control in dogs How to eradicate canine rabies: a perspective of historical efforts Mass vaccination campaign against rabies: are dogs correctly protected? |
| cord-302222-9ad0fw6z | Since ground beef only contributes about one- third of human infections, how could vaccines be used as a means of reducing other sources of food contamination? |
| cord-302222-9ad0fw6z | The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/ FAO meeting ZH501-VSVRI: Is it still the best choice for vaccination against Rift Valley fever in Egypt? |
| cord-302222-9ad0fw6z | Will government agencies concerned with human health subsidize the cost, without empirical demonstration of a human health benefit? |
| cord-302222-9ad0fw6z | understanding the dual- host lifestyle of Lyme disease spirochaetes The emergence of Lyme disease Vaccines against Lyme disease: what happened and what lessons can we learn? |
| cord-302222-9ad0fw6z | what happens on the ground? |
| cord-355689-mo4mvwch | Furthermore, most previous works[ 44][ 45][ 46][ 47][ 48][ 49][ 50][ 51][ 52] often assume that the vaccine has a perfect efficacy, which will endow the complete immunity for the inoculated individuals, but an interesting topic is on how the epidemic spreads when the vaccine is not fully effective for the disease( i.e., 100% efficacy)? |
| cord-355689-mo4mvwch | Hub nodes inhibit the outbreak of epidemic under voluntary vaccination Policy evaluation for the subsidy for influenza vaccination in elderly Does subsidy work? |
| cord-355689-mo4mvwch | The influence of social norms on the dynamics of vaccinating behavior for paediatric infectious diseases Risk assessment for infectious disease and its impact on voluntary vaccination behavior in social networks Can influenza epidemics be prevented by voluntary vaccination? |
| cord-032751-pmclolvh | If your healthcare provider strongly recommended a COVID-19 vaccine in the next year, how likely is it that you'd get vaccinated? |
| cord-032751-pmclolvh | A Bayesian meta- analysis with focus on the Ajzen- Fishbein Model in the field of environmental behavior What is herd immunity, and how does it relate to pediatric vaccination uptake? |
| cord-032751-pmclolvh | Framing HPV to influence vaccination intentions among college students Does changing behavioral intentions engender behavior change? |
| cord-032751-pmclolvh | Perceived threat to physical health was measured with a single item:"If you got infected with COVID-19, how threatening would it be to your physical health?" |
| cord-032751-pmclolvh | Personal susceptibility was measured with a single item:"how likely do you believe it is that you will get infected with COVID-19?" |
| cord-032751-pmclolvh | Reexamining the major tenets of the extended parallel process model Theory- based predictors of influenza vaccination among pregnant women Red media, blue media: Evidence of ideological selectivity in media use Americans'trust in health information sources: Trends and sociodemographic predictors HPV vaccine promotion: Does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior? |
| cord-032751-pmclolvh | Results from the National Immunization Survey- Teen Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? |
| cord-032751-pmclolvh | These two vaccine intent items included"How likely is it that you'll get a COVID-19 vaccine, if it becomes available?" |
| cord-032751-pmclolvh | What are the SARS- CoV-2 vaccine behavioral intentions of adults in the U.S. when a health care provider recommends the vaccine? |
| cord-032751-pmclolvh | What are the SARS- CoV-2 vaccine behavioral intentions of adults in the U.S.? |
| cord-032751-pmclolvh | What factors are associated with SARS- CoV-2 vaccine behavioral intentions of adults in the United States? |
| cord-032751-pmclolvh | Who is to blame? |
| cord-354030-8tfg881h | ( http://unafold.rna.albany.edu/? |
| cord-354030-8tfg881h | Immunoinformatics approach The use of databases, data mining, and immunoinformatics in vaccinology: where are we? |
| cord-354030-8tfg881h | The restriction enzyme cutting sites of Xho? |
| cord-354030-8tfg881h | and BamH? were then appended to the N and C terminals, respectively. |
| cord-317739-2wojtboi | Acknowledgements RS? |
| cord-317739-2wojtboi | Can we determine conditions that optimize vaccine efficacy? |
| cord-317739-2wojtboi | Could vaccination result in a net increase in risk? |
| cord-317739-2wojtboi | For citation purposes, please note that the question mark in"Smith?"is part of his name. |
| cord-317739-2wojtboi | How Far are we? |
| cord-317739-2wojtboi | Which is more important to maximise, vaccination efficacy or use? |
| cord-287067-rrsgl377 | : how does the reality match the predictions? |
| cord-287067-rrsgl377 | Economic evaluations of childhood pneumococcal conjugate vaccination- a review The Global Burden of Disease Assessments- WHO is responsible? |
| cord-287067-rrsgl377 | However, a more simple approach, based on static models, could give insights on the basic question: should we vaccinate girls before their sexual debut? |
| cord-287067-rrsgl377 | Infl uenza vaccine eff ectiveness in healthy 6-to 21-month- old children during the 2003- 2004 season Interdisciplinary epidemiologic and economic research needed to support a universal childhood infl uenza vaccination policy School- based infl uenza vaccination program reduces infl uenza- related outcomes among household members Optimal allocation of pandemic infl uenza vaccine depends on age, risk and timing Convincing or confusing? |
| cord-287067-rrsgl377 | Is G8 putting profi ts before the world's poorest children? |
| cord-287067-rrsgl377 | The seroepidemiology of human papillomavirus infection in Australia Herd immunity: history, theory, practice Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs Evaluating the cost- eff ectiveness of vaccination programmes: a dynamic perspective Eff ectiveness of sevenvalent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case- control study Cost- eff ectiveness of a routine varicella vaccination program for US children Theoretical epidemiologic and morbidity eff ects of routine varicella immunization of preschool children in the United States Impact of anti- vaccine movements on pertussis control: the untold story Eradication versus control for poliomyelitis: an economic analysis Compulsory vaccination and conscientious or philosophical exemptions: past, present, and future Improving uptake of MMR vaccine Cost- eff ectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992- 93 Cost- eff ectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule World wide experience with inactivated poliovirus vaccine Partially wrong? |
| cord-287067-rrsgl377 | Tiered pricing of vaccines: a win- win- win situation, not a subsidy Who benefi ts from new medical technologies? |
| cord-287067-rrsgl377 | do vaccines warrant a different approach? |
| cord-287067-rrsgl377 | thus potentially reshuffl ing the comparison between all health- care programmes( including the other vaccines discussed here)? |
| cord-344750-b9tndbg1 | Can the world find a good covid-19 vaccine quickly enough? |
| cord-344750-b9tndbg1 | Health Policy Inviting free- riders or appealing to prosocial behavior? |
| cord-344750-b9tndbg1 | How Can We Achieve It With COVID-19? |
| cord-344750-b9tndbg1 | How can we develop a COVID-19 vaccine quickly? |
| cord-344750-b9tndbg1 | Tom title: Once we have it, will we use it? |
| cord-318683-1yxurnev | Burkholderia pseudomallei and Burkholderia mallei vaccines: are we close to clinical trials? |
| cord-318683-1yxurnev | Challenges and Opportunities Analysis of historical data suggests long- lasting protective effects of smallpox vaccination Duration of neutralizing antibody persisting in Thai individuals after childhood vaccination against smallpox A model for a smallpox- vaccination policy Can postexposure vaccination against smallpox succeed? |
| cord-318683-1yxurnev | If syndromic surveillance is the answer, what is the question? |
| cord-318683-1yxurnev | Interim final rule and request for comments Destruction of microbial collections in response to select agent and toxin list regulations Implementing the select agent legislation: perfect record or wrong metric? |
| cord-318683-1yxurnev | The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax Specific, sensitive, and quantitative enzyme- linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen Rapid detection of Bacillus anthracis bloodstream infections by use of a novel assay in the GeneXpert System Rapid and sensitive point- of- care detection of orthopoxviruses by ABICAP immunofiltration Rapid viral diagnosis of orthopoxviruses by electron microscopy: optional or a must? |
| cord-318683-1yxurnev | Why do UK military personnel refuse the anthrax vaccination? |
| cord-006252-cbelsymu | Are the side effects a frequent concern? |
| cord-006252-cbelsymu | Are the side effects a frequent concern? |
| cord-006252-cbelsymu | But why is influenza a problem year after year? |
| cord-006252-cbelsymu | But why is influenza a problem year after year? |
| cord-006252-cbelsymu | How effective is influenza vaccine? |
| cord-006252-cbelsymu | How effective is influenza vaccine? |
| cord-006252-cbelsymu | Is it easy to diagnose? |
| cord-006252-cbelsymu | Is it easy to diagnose? |
| cord-006252-cbelsymu | What efforts have been and can be made to improve vaccine acceptance? |
| cord-006252-cbelsymu | What efforts have been and can be made to improve vaccine acceptance? |
| cord-006252-cbelsymu | What is influenza? |
| cord-006252-cbelsymu | What is influenza? |
| cord-006252-cbelsymu | Why the difference? |
| cord-006252-cbelsymu | Why the difference? |
| cord-327650-6afsk8ix | Health 7 Anti- vaccine movement could undermine efforts to end coronavirus pandemic, researchers warn The influence of political ideology and trust on willingness to vaccinate Does partisanship shape attitudes toward science and public policy? |
| cord-327650-6afsk8ix | How Does the World Feel about Science and Health? |
| cord-327650-6afsk8ix | How do individuals come to include a vaccine in the list of objects and decisions upon which they apply their political understanding of the world? |
| cord-327650-6afsk8ix | In countries where vaccine hesitancy was widespread before the COVID-19 epidemic, will it affect the coronavirus vaccination campaign? |
| cord-327650-6afsk8ix | The Politics of Vaccination: A Global History Donald Trump and vaccination: the effect of political identity, conspiracist ideation and presidential tweets on vaccine hesitancy Media Polarization'à la française'? |
| cord-327650-6afsk8ix | When a vaccine will be available, will it be widely used? |
| cord-327650-6afsk8ix | putative future vaccine against COVID-19? |
| cord-289535-srrfr1es | CD8+ T- cell responses after rAd5 boost in a randomized clinical trial BCG- induced trained immunity: can it offer protection against COVID-19? |
| cord-289535-srrfr1es | Can existing live vaccines prevent COVID-19? |
| cord-289535-srrfr1es | Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? |
| cord-289535-srrfr1es | How immune T- cell augmentation can help prevent COVID-19: a possible nutritional solution using ketogenic lifestyle jri/ vol4without altering disease transmission work? |
| cord-289535-srrfr1es | How to achieve equitable global distribution? |
| cord-289535-srrfr1es | Is human challenge part of the pathway to a licensed product? |
| cord-289535-srrfr1es | Is there an ideal animal model for SARS? |
| cord-289535-srrfr1es | Mammalian microRNAs predominantly act to decrease target mRNA levels AU- rich elements and associated factors: are there unifying principles? |
| cord-289535-srrfr1es | Nonspecific protection of mice against influenza virus infection by local or systemic immunization with bacille Calmette- Guerin Is global BCG vaccination coverage relevant to the progression of SARS- CoV-2 pandemic? |
| cord-289535-srrfr1es | What is the risk of immunopathology? |
| cord-289535-srrfr1es | Why Norwood? |
| cord-350565-mejd7blb | 11,323 deaths later, how far have we come? |
| cord-350565-mejd7blb | 2017-what is making elimination so difficult? |
| cord-350565-mejd7blb | : External situation report 9 Use of serological surveys to generate key insights into the changing global landscape of infectious disease Mapping a filoviral serologic footprint in the Democratic Republic of the Congo: who goes there? |
| cord-350565-mejd7blb | A placebocontrolled trial of antimicrobial treatment for acute otitis media Access to new medications for the treatment of drug- resistant tuberculosis: patient, provider and community perspectives Tradeoffs in introduction policies for the anti- tuberculosis drug bedaquiline: a modelbased analysis Population implications of the use of bedaquiline in people with extensively drug- resistant tuberculosis: are fears of resistance justified? |
| cord-350565-mejd7blb | If syndromic surveillance is the answer, what is the question? |
| cord-299315-s43gw24k | But what are the objects, goods, or benefits(and harms) that enable states of heath? |
| cord-299315-s43gw24k | Catastrophic ape decline in western equatorial Africa Potential for Ebola transmission between gorilla and chimpanzee social groups Vaccinating captive chimpanzees to save wild chimpanzees Should protections for research with humans who can not consent apply to research with nonhuman primates? |
| cord-299315-s43gw24k | First, a significant question is'why now?' |
| cord-299315-s43gw24k | How AIDS emerged from an African forest Toward proof of concept of a One Health approach to disease prediction and control From''Us vs. Them''to''Shared Risk'': Can animals help link environmental factors to human health? |
| cord-299315-s43gw24k | Neglected tropical diseases? |
| cord-299315-s43gw24k | Speculations and directions for future research Emerging infections: Condemned to repeat? |
| cord-299315-s43gw24k | The Lancet Can a chimp say''No''? |
| cord-299315-s43gw24k | The duration of the effects of repeated widespread badger culling on cattle tuberculosis following the cessation of culling Has culling been properly assessed as a valid and justified control intervention measure for zoonotic diseases? |
| cord-299315-s43gw24k | Why are clinicians still empty- handed, with no vaccines and no cure? |
| cord-299315-s43gw24k | Why only now has the Ebola virus, which has previously emerged in isolated regions, become a regional endemic( Olival and Hayman 2014; Olson et al. 2012)? |
| cord-265472-b1s4stvz | 5 case reports Cutaneous polyarteritis nodosa in a child following hepatitis B vaccination Systemic polyarteritis nodosa following hepatitis B vaccination Kawasaki disease in an infant following immunisation with hepatitis B vaccine Yellow fever vaccination and Kawasaki disease Churg- strauss vasculitis with brain involvement following hepatitis B vaccination ANCA- associated vasculitis following influenza vaccination: causal association or mere coincidence? |
| cord-265472-b1s4stvz | : does it induce autoimmunity and cutaneous sclerosis? |
| cord-265472-b1s4stvz | A review on the association between inflammatory myopathies and vaccination Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes Etiology of fibromyalgia: the possible role of infection and vaccination Infection and vaccination in chronic fatigue syndrome: myth or reality? |
| cord-265472-b1s4stvz | Bullous pemphigoid after herpes zoster vaccine administration: association or coincidence? |
| cord-265472-b1s4stvz | Can immunisation trigger rheumatoid arthritis? |
| cord-265472-b1s4stvz | Does influenza vaccination induce bullous pemphigoid? |
| cord-265472-b1s4stvz | The immunobiology of aluminium adjuvants: how do they really work? |
| cord-265472-b1s4stvz | The mosaic of autoimmunity Infections and autoimmunity- friends or foes? |
| cord-265472-b1s4stvz | The pro- oxidant activity of aluminum Regulatory role of zinc during aluminium- induced altered carbohydrate metabolism in rat brain Aluminum and Alzheimer's disease: after a century of controversy, is there a plausible link? |
| cord-265472-b1s4stvz | Vaccine safety datalink team Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years Risk of yellow fever vaccine- associated viscerotropic disease among the elderly: a systematic review Bacillus calmette- guérin immunotherapy for genitourinary cancer Arthritis after BCG vaccine in a healthy woman Dermatomyositis after B.C.G. vaccination Aetiopathogenesis of Takayas's arteritis and BCG vaccination: the missing link? |
| cord-265472-b1s4stvz | anti- TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice Is narcolepsy a classical autoimmune disease? |
| cord-265472-b1s4stvz | autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? |
| cord-265472-b1s4stvz | following human papillomavirus vaccination HBV vaccine and dermatomyositis: is there an association? |
| cord-265472-b1s4stvz | interferon alpha-2b confer additional benefit in the adjuvant treatment of high- risk melanoma? |
| cord-265472-b1s4stvz | vaccination- a case report Human papillomavirus( HPV) vaccine policy and evidence- based medicine: are they at odds? |
| cord-010266-elhgew3x | And indeed, is it ethical that a person in the vaccine- producing country should enjoy the benefits which have been won at the expense of the risk- taking of a person in less privileged circumstances? |
| cord-010266-elhgew3x | Are the conditions leading to infection and the challenge organisms relevant? |
| cord-010266-elhgew3x | Are the people in whom the vaccine is tested likely to respond in an immunologically equivalent manner when the history of the exposure of their immune systems to disease is dissimilar in many ways to a person of the Developed World? |
| cord-010266-elhgew3x | But how safe is safe? |
| cord-010266-elhgew3x | But is this the appropriate ethic? |
| cord-010266-elhgew3x | Does this mean that the rich should pay a high price for a vaccine and thus subsidize the provision of cheap vaccines to the poor? |
| cord-010266-elhgew3x | For example, is it possible to obtain the informed consent of a person who is illiterate and who does not understand the implications of something like a vaccine with which( s)he is totally unfamiliar? |
| cord-010266-elhgew3x | In the event that there is damage to an individual as a result of exposure to vaccine in a trial, what are the levels of compensation and who pays? |
| cord-010266-elhgew3x | Is it appropriate to use a technical fix when an almost cost- free change of behaviour will achieve the same effect? |
| cord-010266-elhgew3x | May not the society, in accepting the benefit of widespread vaccination, compensate those who suffer damage at a level communsurate with the damage? |
| cord-010266-elhgew3x | One might ask, to what extent is a prophylactic trial in the Developing World relevant to the circumstances prevalent in the Developed World? |
| cord-010266-elhgew3x | Or is it the job of the elected representatives of the people to act as purchaser on behalf of the poor and provide the vaccine manufacturer compensation through the tax system or other fiscal dispensation? |
| cord-010266-elhgew3x | The question which this poses is, do those who have opted against vaccination have the right to benefit from the expense and the risks of vaccine- induced damage accepted by those who have been vaccinated? |
| cord-010266-elhgew3x | Were the genes of that cell to be used to make a pharmaceutical to particularly benefit people in the Developed World, what sort of compensation should acrue to the source of the cell line from which the gene was obtained? |
| cord-010266-elhgew3x | and what are the limits by which we define consistency? |
| cord-010266-elhgew3x | and what is efficacious? |
| cord-311112-cg7wqc0q | -How long does it actually take to develop a vaccine, generally? |
| cord-311112-cg7wqc0q | A decade after SARS: strategies for controlling emerging coronaviruses Chikungunya virus control: is a vaccine on the horizon? |
| cord-311112-cg7wqc0q | Do you expect that we'll be continuing to see emerging infections we have n't seen before? |
| cord-311112-cg7wqc0q | Do you have any view on that possibility? |
| cord-311112-cg7wqc0q | Do you think this is going to have to change in the light of what has happened with Ebola? |
| cord-311112-cg7wqc0q | I know that there are'flu vaccines, but are there licensed vaccines for any of the others? |
| cord-311112-cg7wqc0q | Is that the only difficultly, or are there other difficulties in developing vaccines for these sorts of diseases? |
| cord-311112-cg7wqc0q | What about the possibility, aired in the Press, that Ebola might become transmissible in an airborne form? |
| cord-311112-cg7wqc0q | do we need to be? |
| cord-339091-3xk2w0d2 | Are apparently high- scoring matches real or an artefact of search methodology? |
| cord-339091-3xk2w0d2 | Are bacterial vaccine antigens T- cell epitope depleted? |
| cord-339091-3xk2w0d2 | But how can we progress beyond this rather inexactly- specified philosophical standpoint to something which is practically useful when we select vaccine candidates? |
| cord-339091-3xk2w0d2 | EPIMHC: a curated database of MHC- binding peptides for customized computational vaccinology AntiJen: a quantitative immunology database integrating functional, thermodynamic, kinetic, biophysical, and cellular data JenPep: a novel computational information resource for immunobiology and vaccinology JenPep: a database of quantitative functional peptide data for immunology Bacterial virulence: can we draw the line? |
| cord-339091-3xk2w0d2 | Have we cut ourselves too short in mapping CTL epitopes? |
| cord-339091-3xk2w0d2 | It would indeed be wonderful if the identification of candidate vaccines was really and consistently this simple and systematic? |
| cord-339091-3xk2w0d2 | Obviously, all the same caveats that exist for any sequence search hold here also: which thresholds are appropriate? |
| cord-257582-e9306xae | At what age do you give the first dose of rabies vaccine to a puppy? |
| cord-257582-e9306xae | Can I give core vaccination to puppies at 4 weeks of age if they are due to be sold at 6 weeks of age? |
| cord-257582-e9306xae | Do you give a second dose of rabies vaccine to a puppy? |
| cord-257582-e9306xae | Do you recommend revaccinating adult dogs against rabies? |
| cord-257582-e9306xae | Do you use other vaccines in addition to the core vaccines( CDV, CAV2 and CPV2) in adult dogs? |
| cord-257582-e9306xae | Feline vaccine- associated sarcomagenesis: is there an inflammation- independent role for aluminium? |
| cord-257582-e9306xae | Here, the veterinary professional needs to ask the question"who is making this regulation"? |
| cord-257582-e9306xae | How can we safely socialise puppies if they are potentially susceptible to infection( because they are in the"window of susceptibility") at the optimum time for socialisation? |
| cord-257582-e9306xae | If a dog has recovered from an immune- mediated disease that may have been triggered by vaccination; how should I revaccinate it in the future? |
| cord-257582-e9306xae | If so, at what age? |
| cord-257582-e9306xae | If so, how frequently should they be revaccinated? |
| cord-257582-e9306xae | If so, which ones and how frequently do you give them( i.e. annually? |
| cord-257582-e9306xae | More or less often?) |
| cord-257582-e9306xae | Should elderly dogs be vaccinated every year with core vaccines because their immune system might not function as well as when they were younger? |
| cord-257582-e9306xae | Should the puppies be vaccinated immediately, rather than waiting until their next scheduled vaccination day? |
| cord-257582-e9306xae | Until which age should I vaccinate an elderly dog? |
| cord-257582-e9306xae | Why should shelter puppies be vaccinated every 2 weeks from 6 weeks of age to 20 weeks of age if it has been shown that puppies may have persistent maternally- derived antibody until 16 weeks of age? |
| cord-257582-e9306xae | a possible new CPV-2a is emerging? |
| cord-257582-e9306xae | implications from a field study in kittens Three- year duration of immunity in cats vaccinated with a canarypox- vectored recombinant rabies virus vaccine Three- year duration of immunity for feline herpesvirus and calicivirus evaluated in a controlled vaccination- challenge laboratory trial Serum survey for antibodies to coronavirus, herpesvirus, calicivirus, and parvovirus in domestics cats from Rio Grande do Sul, Brazil Zoonotic intestinal helminths interact with the canine immune system by modulating T cell responses and preventing dendritic cell maturation Prevention of feline injection- site sarcomas: is there a scientific foundation for vaccine recommendations at this time? |
| cord-276209-5999g9gp | -Could a vaccine be provided through a revised definition of a compassionate use mechanism in the highest risk subjects after signing waivers of responsibility and enhanced informed- consent procedures? |
| cord-276209-5999g9gp | -Might one conceive of differential regulatory pathways for vaccine candidates using well- understood antigens, vaccine methodology, adjuvants, manufacture, and routes of administration( TBD) versus those using novel delivery technology and novel antigens or adjuvants? |
| cord-276209-5999g9gp | -What will be the endpoint for determining vaccine efficacyprevention of infection? |
| cord-276209-5999g9gp | -What, if any, animal models might be developed that allow the''animal rule"to be utilized in an effort to accelerate research and licensure? |
| cord-276209-5999g9gp | Could this be a viable strategy in accelerating licensure? |
| cord-276209-5999g9gp | For example, what level of risk are we willing to tolerate to immunize against an infection that may disappear in the next year or two? |
| cord-276209-5999g9gp | I and II trials are conducted earlier than normal procedure, could a phased initiation of studies from highest risk to lowest risk subjects be utilized? |
| cord-276209-5999g9gp | Might reasonable''accommodations"be made for such a scenario? |
| cord-276209-5999g9gp | Might that safety profile be somewhat different( to be defined) in an exceptionally high risk 80-yearold with multiple co- morbidities? |
| cord-276209-5999g9gp | Or that could diminish in severity in the short- to mid- term? |
| cord-276209-5999g9gp | Or to administer to young children whose risk of both serious illness or death is quantifiably very, very low? |
| cord-276209-5999g9gp | Other?-Will |
| cord-276209-5999g9gp | Prevention of severe disease? |
| cord-276209-5999g9gp | Prevention of viral shedding? |
| cord-276209-5999g9gp | Several seem worth immediate discussion:-Could a vaccine be provided through an EUA mechanism for mentally competent adults who meet certain risk guidelines, and in the context of study enrollment and data collection, and enhanced informed consent? |
| cord-276209-5999g9gp | What about for pregnant women or younger but immunocompromised persons? |
| cord-276209-5999g9gp | What does history teach us in regard to vaccine development? |
| cord-276209-5999g9gp | Who should be included- perhaps healthcare providers and first responders who share the highest risk of infection as a starting point? |
| cord-276209-5999g9gp | different vaccines and different regulatory pathways be feasible for different members of the population with differing risk: benefit ratios? |
| cord-285760-y37ji92k | 9 strain of live attenuated mumps vaccine in comparison with the Jeryl Lynn strain Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity Primary vaccine failure after 1 dose of varicella vaccine in healthy children Outbreak of mumps in a vaccinated child population: a question of vaccine failure? |
| cord-285760-y37ji92k | : a ten year longitudinal cohort study of American children born in the 1990s Duration of humoral immunity to common viral and vaccine antigens Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? |
| cord-285760-y37ji92k | Available online at: https://vaccineschedule.ecdc.europa.eu/Scheduler/ByDisease? |
| cord-285760-y37ji92k | Correlates of lymphoproliferative responses to measles, mumps, and rubella( MMR) virus vaccines following MMR- II vaccination in healthy children Detection of mumps virus- specific memory B cells by transfer of peripheral blood mononuclear cells into immune- deficient mice Are cases of mumps in vaccinated patients attributable to mismatches in both vaccine T- cell and B- cell epitopes? |
| cord-285760-y37ji92k | Does the medical profession and the"pro- vaccine"message contribute to the public skepticism regarding immunization? |
| cord-285760-y37ji92k | How is a response to a vaccine determined? |
| cord-285760-y37ji92k | Is it time to shift the medical and public perception paradigm from"protection of infection following vaccination"to"protection from serious clinical mumps manifestation"? |
| cord-285760-y37ji92k | Molecular signatures of antibody responses derived from a systems biology study of five human vaccines Influenza immunization elicits antibodies specific for an egg- adapted vaccine strain Influenza vaccine failure: failure to protect or failure to understand? |
| cord-285760-y37ji92k | RT%2DPCR%20and% 20viral%20culture, aid%20in%20diagnosing%20mumps%20infection Diagnosis of acute mumps infection during an outbreak in a highly vaccinated population: mumps RNA or mumps IgM detection? |
| cord-285760-y37ji92k | The case numbers of more recent mumps outbreaks should always be assessed with this question in mind; are the number of mumps cases increasing, or/ and are we better at diagnosing an acute infection? |
| cord-285760-y37ji92k | The establishment of surrogates and correlates of protection: useful tools for the licensure of effective influenza vaccines? |
| cord-285760-y37ji92k | The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine Trained immunity- based vaccines: a new paradigm for the development of broad- spectrum anti- infectious formulations Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? |
| cord-285760-y37ji92k | Therefore, does"immunity"refer to sterile immunity or solely to protection from symptomatic infection? |
| cord-285760-y37ji92k | Therefore, if a correlate or surrogate correlate is unobtainable to define an individual's protection to mumps, should we re- consider and re- focus efforts on optimizing the vaccine using available historical clinical and trial data? |
| cord-285760-y37ji92k | What defines an effective vaccine, or what constitutes vaccine failure? |
| cord-285760-y37ji92k | Why Do We Consider Antibodies to Be the Best Measurement of Vaccine Efficacy? |
| cord-285760-y37ji92k | key: cord-285760-y37ji92k authors: Connell, Anna R.; Connell, Jeff; Leahy, T. Ronan; Hassan, Jaythoon title: Mumps Outbreaks in Vaccinated Populations — Is It Time to Re- assess the Clinical Efficacy of Vaccines? |
| cord-285760-y37ji92k | the nova scotia experience Mumps outbreak and laboratory diagnosis Antibody Fab- Fc properties outperform titer in predictive models of SIV vaccine- induced protection Increase in mumps in Ireland in late Assessment of mumps virus- specific antibodies by different serological assays: which test correlates best with mumps immunity? |
| cord-285760-y37ji92k | why and what to do? |
| cord-021966-5m21bsrw | > Having chosen an antigen and presentation system, what is the best way to produce it on a large scale? |
| cord-021966-5m21bsrw | A review of the Vaccine Adverse Event Reporting System database Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines Permanent brain damage and pertussis vaccination: is the end of the saga in sight? |
| cord-021966-5m21bsrw | Can a specific antigen( or antigens) be identified that represents the target of protective host immune responses? |
| cord-021966-5m21bsrw | Can the pathogen be grown in culture? |
| cord-021966-5m21bsrw | Even larger phase IIb studies can provide additional data on vaccine safety and immunogenicity in subjects generally representative of those for whom the vaccine might be recommended, but importantly, also provide the first opportunity to address to answer the question,'Does this vaccine work in humans?' |
| cord-021966-5m21bsrw | If natural immunity capable of preventing re- infection follows an initial infection with the pathogen, can a specific host immune effector mechanism( e.g., antibody, CD8 T- cell) be identified as the likely agent( or'correlate') of immune protection? |
| cord-021966-5m21bsrw | If so, can a threshold level of this specific immune correlate needed for protection from re- infection be defined? |
| cord-021966-5m21bsrw | If so, does the pathogen cause such a life- threatening disease that an attenuated version of the virus would face an impossible barrier for demonstration of safety? |
| cord-021966-5m21bsrw | If the infection occurs relatively rarely in an overall population, can a subset of the population be identified that has a higher risk of infection so as to accelerate the achievement of statistically significant protection? |
| cord-021966-5m21bsrw | If the protective immune response is mediated by antibodies, can the target antigen( be it a protein or polysaccharide) be produced in scalable quantities in a form that mimics its native structure so that it can effectively elicit antibody responses that can block the key functional role(s) of the target molecule in the pathogen lifecycle or otherwise lead to the clearance of an incipient pathogen infection? |
| cord-021966-5m21bsrw | Is immunity to a given antigen associated with protection against disease following re- exposure in the context of natural infection? |
| cord-021966-5m21bsrw | Is the antigen of interest sufficiently immunogenic on its own, or is augmentation of the desired immune response by conjugation to a specific carrier or addition of an adjuvant necessary to elicit a sufficient and sufficiently durable immune response in individuals in the target population for vaccination? |
| cord-021966-5m21bsrw | Is this subset sufficiently similar to the rest of the population to enable extrapolation of the clinical results to the broader target population as a whole? |
| cord-021966-5m21bsrw | Recent advances in the development of HIV-1 vaccines using replication- incompetent adenovirus vectors One step forward, two steps back-will there ever be an AIDS vaccine? |
| cord-021966-5m21bsrw | The MMR vaccination and autism controversy in United Kingdom 1998- 2005: inevitable community outrage or a failure of risk communication? |
| cord-021966-5m21bsrw | What are the major unmet medical and public health needs today? |
| cord-021966-5m21bsrw | What is known about the natural history and pathogenic mechanisms of the infection of interest? |
| cord-021966-5m21bsrw | What is the attack rate of the infection in the general population? |
| cord-021966-5m21bsrw | What is the most effective way to present the antigens of the pathogen of interest to the immune system? |
| cord-021966-5m21bsrw | What tests to evaluate vaccine immunogenicity will need to carried out on clinical samples obtained from participants in the clinical trials? |
| cord-021966-5m21bsrw | What types of potential safety concerns can be anticipated for the vaccine in question? |
| cord-021966-5m21bsrw | Will measurement of antibody titers, T- cell responses, pathogen presence and quantity, pathogen serotype, and any other parameter peculiar to the disease in question represent the primary criteria for vaccine effect? |
| cord-343365-4y9fedcr | Autoimmune Lung Diseases- Biomarkers and Biologics- Sparing the Steroids? |
| cord-343365-4y9fedcr | But how will this be done? |
| cord-343365-4y9fedcr | But where did this virus come from and how did it suddenly cause so much havoc? |
| cord-343365-4y9fedcr | Cystic Fibrosis- What Happened to Gene Therapy? |
| cord-343365-4y9fedcr | How close are we to implementing gene targeting in animals other than the mouse? |
| cord-343365-4y9fedcr | Is this a failure of an immunization program? |
| cord-343365-4y9fedcr | Molecular basis of binding between novel human coronavirus MERS- CoV and its receptor CD26 Anti- neutrophil cytoplasmic antibody( ANCA)-associated vasculitis: where to go? |
| cord-343365-4y9fedcr | Respiratory Syncytial Virus- How to Develop an Effective Vaccine? |
| cord-343365-4y9fedcr | So can SARS happen again? |
| cord-343365-4y9fedcr | So, what happened to gene therapy? |
| cord-343365-4y9fedcr | The genomics of autoimmune disease in the era of genome- wide association studies and beyond The genomics and Personalized Medicine Act of Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? |
| cord-343365-4y9fedcr | The role of environmental estrogens and autoimmunity Systemic lupus erythematosus one disease or many? |
| cord-343365-4y9fedcr | The role of the environment in the development of pediatric inflammatory bowel disease Do infections facilitate the emergence of systemic sclerosis? |
| cord-343365-4y9fedcr | Treatment of ANCA- associated vasculitis, where to go? |
| cord-343365-4y9fedcr | Tuberculosis vaccines: time to reset the paradigm? |
| cord-343365-4y9fedcr | What are the prospects for gene therapy in the twenty- first century? |
| cord-343365-4y9fedcr | What happened to all that promise that buoyed the cystic fibrosis community back in the 1980s? |
| cord-343365-4y9fedcr | how are they detected and what is their use for diagnosis, classification and follow- up? |
| cord-285128-48l1w65p | Are there antiviral or other treatments available for disease manifestations caused by the vaccine? |
| cord-285128-48l1w65p | Does an animal model for antibody enhanced disease or immune complex disease exist? |
| cord-285128-48l1w65p | Does an animal model for immunogenicity and efficacy exist? |
| cord-285128-48l1w65p | Does an animal model for reproductive toxicity exist? |
| cord-285128-48l1w65p | Does an animal model for safety including immuno- compromised animals exist? |
| cord-285128-48l1w65p | Does an animal model relevant to assess attenuation exist? |
| cord-285128-48l1w65p | Does the vaccine replicate in the nucleus? |
| cord-285128-48l1w65p | For replicating vectors, has a comparative virulence and viral kinetic study been conducted in permissive and susceptible species? |
| cord-285128-48l1w65p | How is the transgene expression controlled( transcriptional promoters, etc.)? |
| cord-285128-48l1w65p | If not, what species would be used for such a study? |
| cord-285128-48l1w65p | Is it feasible to conduct such a study? |
| cord-285128-48l1w65p | Is the vaccine replicationcompetent in humans or other species? |
| cord-285128-48l1w65p | Is the vaccine transmissible in humans or other species( including arthropods) and/or stable in the environment? |
| cord-285128-48l1w65p | Nonhuman primates( NHP)? |
| cord-285128-48l1w65p | Pregnancy and in the unborn in humans? |
| cord-285128-48l1w65p | Small animal models? |
| cord-285128-48l1w65p | What is known about biodistribution in animal models or in humans? |
| cord-285128-48l1w65p | What is known about the effect of pre- existing immunity, including both natural immunity and repeat administration of the vector or the vaccine, on'take', safety or efficacy in any animal model or human studies using this vector? |
| cord-285128-48l1w65p | What is known about the mechanisms of immunity to the vaccine? |
| cord-285128-48l1w65p | What is the potential for shedding and transmission in risk groups? |
| cord-285128-48l1w65p | What is the potential for shedding and transmission to humans or other species? |
| cord-285128-48l1w65p | What is the potential for shedding and transmission to humans or other species? |
| cord-285128-48l1w65p | What is the risk of integration into the human genome? |
| cord-285128-48l1w65p | What is the risk of reversion to virulence or recombination with wild type or other agents? |
| cord-285128-48l1w65p | What is the risk of reversion to virulence or recombination with wild type virus or other agents? |